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CHAPTER I 
 
 
INTRODUCTION 
 
 
Neuroblastoma 
Cancer is the second leading cause of death in pediatric population younger 
than 15 years of age [1]. Neuroblastoma represents 7~10% of children cancers and 
is the most common extra-cranial solid tumor in infants and children [2]. It accounts 
for greater than 15% of all pediatric cancer-related deaths [3]. The overall mortality 
for all stages of tumors remains significant at 50%; advanced-stage tumors are 
highly refractory to current treatment modalities [4]. Approximately 700 new cases 
are reported for neuroblastoma in the United States each year, nearly half of which 
present in toddlers < 2 years of age [5]. Considering the incidence of neuroblastoma 
at such a young age, the potential successful treatment would be able to result in the 
preservation of significant life-span years. Despite remarkable recent advancement 
in pediatric cancer therapy including surgery, radiotherapy and chemotherapy, the 5-
year survival rate for patients with advanced disease is a dismal 50% and associated 
with severe long-term complications [6,7]. Importantly, two thirds of neuroblastoma 
patients present with metastases at the time of diagnosis and usually metastases 
occur in the bone marrow, liver, lymph nodes, skin and brain. In addition, most 
children in stage 4 that are treated for this disease will frequently experience a 
relapse of tumor growth. As a sympathetic neural crest derived tumors, 
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neuroblastoma can occur anywhere in the location of sympathetic nervous system; 
however, adrenal medulla is the most frequent primary site. One of the most unique 
aspects of neuroblastoma is its wide spectrum of clinical presentations, ranging from 
spontaneous remission to rapid tumor progression [8]. Infants with stage 4S disease 
can have a favorable prognosis with potential for spontaneous tumor regression 
[9,10,11].  
Neuroblastoma is categorized by the degree of cellular differentiation of tumor 
cells; ganglioneuroma is well-differentiated benign tumors with mature ganglion cells, 
neuroblastoma is poorly-differentiated tumors with abundant neuroblast cells and 
ganglioneuroblastoma is an intermediary category possessing features of both the 
immature neuroblastomas and differentiated ganglioneuromas [12,13]. 
Neuroblastoma is also characterized by several molecular markers that correlate to 
various degrees of prognosis, for example, MYCN, cell surface glycoprotein CD44, 
and tyrosine kinase receptors TrkA and TrkB. In particular, MYCN is the most well 
known marker in neuroblastoma. Approximately 25% of primary neuroblastomas 
demonstrate MYCN amplification, which is strongly correlated with advanced-stage 
tumors and poor prognosis [14,15,16,17] (Table 1). MYCN amplification in 
neuroblastoma is typically characterized by florid vascularization [14,15,16]. 
Moreover, MYCN amplification has been associated with other poor prognostic 
indicators such as chromosome 1p deletion as well as enhanced multidrug 
resistance-associated protein (MRP) expression [18,19]. Additionally, our laboratory 
and others have shown that the MYCN expression is regulated by 
phosphatidylinositol 3-kinase (PI3K)/AKT pathway [20,21]. Thereby, PI3K/AKT 
pathway is a potent regulator of vascular endothelial growth factor (VEGF), which  
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Table 1. Neuroblastoma risk-group criteria [17] 
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correlates with unfavorable histology and aggressive neuroblastomas [22,23]. Our 
laboratory has evaluated the role of MYCN in the regulation of PI3K-mediated VEGF 
expression. We have found that MYCN plays an important role in PI3K-mediated 
VEGF regulation in neuroblastoma cells by targeting MYCN as a novel effector of 
PI3K-mediated VEGF [21]. Furthermore, other groups have demonstrated that 
MYCN binds to the promoter of focal adhesion kinase (FAK) and activates FAK 
expression in MYCN-amplified neuroblastoma cell lines [24,25], suggesting FAK 
expression is correlated with amplification of the MYCN oncogene in neuroblastoma 
cells. In addition, neuroblastomas have the notable ability to interact with their 
microenvironment in order to promote cell survival and that can manipulate autocrine 
and paracrine growth signals to enhance its pathogenesis [26]. Neuroblastomas are 
classified as amine precursor uptake decarboxylase tumors and hence, they secrete 
peptides and other substances including vasoactive intestinal polypeptide, 
catecholamines, and gastrin-releasing peptide (GRP) [26,27,28]. These peptides 
may be involved in the regulation of tumorigenesis and their expressions have been 
correlated with clinical tumor behavior.  
Overall, combination therapy with surgical resection, chemotherapy and 
targeted radiation has been developed and is a mainstay for patients with advanced 
primary, refractory or metastatic neuroblastoma. However, these therapeutic 
advances have failed to significantly increase the 5-year survival rates and current 
chemotherapeutic regimens are usually unsuccessful at effectively eradicating the 
disease. Furthermore, the toxicities remain a significant problem. This is why 
pediatric neuroblastomas that are enigmatic, multifaceted tumors continue to remain 
a clinical challenge. Hence, development of additional adjuvants may be required for 
the benefits of chemotherapy while decreasing the harmful side effects. Moreover, 
 5 
since neuroblastomas are highly heterogeneous, it is important to focus on 
addressing the various pathogenic intricacies of this tumor. Understanding the 
various biological and molecular components regulating neuroblastoma progression 
is necessary to successfully improve survival rates of pediatric patients with high-risk 
neuroblastoma and may lead to innovative therapeutic agents for more effective 
combinational therapy.  
 
Gastrin-Releasing Peptide (GPR) and GRP-receptor (GRPR) 
As a gut/neuropeptide, GRP is found in the gut and brain with a stimulatory 
effect on the growth of various tissues [29,30]. GRP induces the release of gastrin 
and other neurotransmitters (i.e., neurotensin, somatostatin), which can then 
regulate secretion and/or hormone release from the numerous endocrine organs 
[31,32,33]. Moreover, GRP can regulate cell growth directly by stimulating DNA 
synthesis and cell replication [32,34] and increase invasiveness of prostate cells 
through enhanced cell motility [35].  
GRPR is a member of the family of G-protein-coupled receptors (GPCRs) 
that have seven transmembrane domains. A GPCR is a large family of cell surface 
receptors that is coupled to G-proteins. G proteins are a family of similar proteins 
located in the plasma membrane and are specialized proteins with the ability to bind 
the nucleotides, guanosine triphosphate (GTP) and guanosine diphosphate (GDP). 
When activated, they undergo conformational changes by binding or hydrolyzing 
GTP to modify channel gates in the cellular membrane. In this way, the receptors are 
coupled to intracellular responses. Specifically, GRPR is abnormally expressed in 
various cancers of the breast [36], lung  [37], stomach [36], pancreas [38], prostate 
[39] and colon [40], indicating GRPR may function as a biomarker for cancer 
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progression and can potentially serve as an effective target for anti-cancer therapy. 
Likewise, cancer cells express GRPR and secrete GRP acting as an autocrine 
growth factor. As a neuroendocrine tumor, neuroblastoma frequently expresses and 
secretes gastrointestinal hormones, for example, GRP, vasoactive intestinal peptide, 
somatostatin, neurotensin, gastrin, and cholecystokinin. These peptides are found to 
exert various autocrine, paracrine, and endocrine functions in neuroblastoma cells 
[41,42]. However, their exact role in the regulation of cell proliferation is not yet fully 
elucidated. 
Clearly, endocrine hormones, acting as mitogens for stimulation of tumor 
growth is important in terms of cellular function in neuroendocrine tumors. Similarly, 
it has become more evident that neuroendocrine peptides can represent an 
important tumor marker as well as a potential target for novel treatment strategies for 
neuroblastoma. Therefore it is important to discuss the mitogenic actions of a 
specific peptide, GRP, and the cellular mechanisms involved in GRP/GRPR-
mediated neuroblastoma cell growth response. Our laboratory has discovered the 
increased expression of GRP and GRPR in human neuroblastoma tissue sections 
(Fig. 1) and the signaling cascades that take place after GRP binds to GRPR in 
neuroblastoma; GRP treatment increased growth in neuroblastoma cell lines by 
inducing calcium influx into the cells [43], which can activate phospholipase C (PLC) 
and transduce mitogen-activated protein kinase (MAPK) signaling through protein 
kinase C (PKC) and calcium. We have also discovered a relationship between GRP 
signaling and PI3K pathway [44]. Moreover, PI3K inhibition destabilizes the protein 
levels of neuroblastoma oncogene MYCN [20,21], and further we have found that 
PI3K regulates mediators of angiogenesis through MYCN-dependent pathways [21]. 
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Figure 1. GRP/GRPR expression in human neuroblastoma sections. Representative 
images of two subtypes of human neuroblastomas showing differential GRP and GRPR 
expression by immunohistochemical staining (100X). Increased expression of GRP and 
GRPR protein (shown by the brown staining) is noted in undifferentiated neuroblastoma 
compared with well-differentiated ganglioneuroma [43].       
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In addition, we have reported that GRPR overexpression decreased 
phosphatase and tensin homolog (PTEN) expression and increased activated AKT 
expression in neuroblastoma cells [44]. However, still the exact molecular 
mechanisms by which GRP/GRPR signaling is involved in neuroblastoma growth 
and metastasis and their functional role in regulating neuroblastoma progression are 
not clearly elucidated. Moreover, GRP transduction cascade is inherently more 
complex and a relationship between GRPR and its downstream pathway has not 
been fully defined. A better understanding of the molecular mechanisms involved in 
GRP/GRPR signaling is necessary to understand neuroblastoma progression. This 
could result in the development of better specific therapeutic targets for 
neuroblastoma. 
Its high expression in a large spectrum of human cancers, as well as the 
demonstration of its role as a tumor growth factor in various tumor models gives 
support to study GRP/GRPR antagonists as anticancer agents. GRP/GRPR 
antagonists have been developed as anticancer candidate compounds, exhibiting 
impressive antitumor activity in various murine and human tumors in vitro and in vivo 
[45,46]. In an animal model of chemical-induced oral cancer, a GRP antagonist has 
been shown to prevent the formation of malignant tumor lesions [47]. Furthermore, 
selective GRPR antagonists attenuated GRP-stimulated tumor growth and 
angiogenic markers in vivo. In addition, the interference with GRP/GRPR signaling 
was shown to have indirect effects upon other intracellular signaling pathways, which 
was already shown to have clinical importance in cancer therapy, such as the 
inhibition of VEGF-dependent tumor angiogenesis and epidermal growth factor 
(EGF)-dependent tumor growth [48,49,50,51,52,53]. 
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Clinical trials with GRP/GRPR antagonists in cancer patients are in the initial 
phase, and as anticipated by animal toxicology studies, preliminary evaluation in 
humans did not indicate the existence of major toxic effects limiting to normal tissue 
[54]. A phase I trial was recently conducted in an institution to determine the safety 
and feasibility of RC-3095, a GRPR antagonist to 25 patients with advanced solid 
malignancies [55]. Despite of the fact that the promising results in the preclinical 
setting have been observed by targeting GRP/GRPR expression using monoclonal 
antibodies or their antagonists, still limited anti-tumor effects have been observed 
when these agents have been administered to cancer patients. Presently, efforts to 
identify the most suitable candidates and to improve the formulation of drug for 
human use are considered priorities [46].  
 
Focal Adhesion Kinase (FAK) 
FAK is a 125-kDa cytoplasmic protein tyrosine kinase that plays an essential 
role during embryonic development and in the pathogenesis of human disease, 
including cancer and cardiovascular disease [56,57,58]. FAK is expressed in most 
tissues and its sequence is highly conserved across species and its expression has 
increased in invasive and metastatic human cancers including breast cancer, colon 
cancer, ovarian cancer, thyroid cancer, melanoma, and sarcoma [59,60,61] 
compared to normal tissue [62]. In normal cells, FAK and adhesion signaling 
pathways are involved in important cellular processes, including development, 
vascular function, and repair while in cancer cells, FAK expression and activation 
play a wide variety of roles in cell survival, proliferation, migration and invasion that 
are crucial in the progression and malignancy of tumors. For these reasons, many 
studies have investigated the exact role of FAK in the regulation of these processes.  
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FAK is composed of three major domains: the N-terminal band 4.1, ezrin, 
radixin, moesin homology (FERM) domain, the central kinase domain, and the C-
terminal focal adhesion-targeting (FAT) domain. Activation occurs when integrin 
interacts with the FERM domain, exposing the catalytic site, resulting in 
autophosphorylation of FAK at tyrosine 397 (Y397), which creates docking sites for 
proteins with Src homology 2 (SH2) domains, specifically Src, the p85 subunit of 
PI3K, Grb7, and PLC [63,64]. Phosphorylated FAK can recruit and bind the SH2 
domain of several other molecules including Src and PI3K and FAK phosphorylates 
other tyrosine residues including residues Y576 and Y577 in the kinase activation 
loop resulting in further activation. These phosphorylation events are required for 
initiating a cascade of phosphorylation events and new protein-protein interactions to 
trigger numerous signaling pathways. FAK signaling pathways have shown to be 
important to regulate a variety of intracellular functions including cell spreading, 
migration, invasion, proliferation, survival, and apoptosis in both normal cell 
development and cancer cell progression (Fig. 2).  
Meanwhile, the abundant expression of both FAK mRNA and protein in 
aggressive human neuroblastoma tumors has been reported [24]. In addition, it has 
been demonstrated that MYCN regulates the expression of FAK through its promoter 
in human neuroblastoma cells so that FAK is overexpressed in MYCN amplified 
neuroblastoma cells compared to MYCN non-amplified cells [25]. Moreover, 
inhibition of FAK has resulted in decreased cellular attachment and increased 
cellular apoptosis in these cells [65]. Furthermore, use of small molecule inhibitors in 
human neuroblastoma has also been reported. FAK inhibition with TAE226 
treatment of MYCN amplified neuroblastoma cells results in significantly decreased 
cell viability with minimal effects upon MYCN non-amplified cells [66]. Additionally,  
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Figure 2. FAK signaling pathways. FAK is an important mediator of interacting various 
proteins and signaling cascades that are involved in apoptosis, cell survival, proliferation, 
migration, angiogenesis and lymphogenesis. Interaction with integrins and growth-factor 
receptors as well as intracellular kinases causes a conformational change in FAK and 
induces activation of FAK. This initiates a cascade of phosphorylation events of other 
downstream proteins and new protein-protein interactions to trigger numerous signaling 
pathways. 
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treatment with 1, 2, 4, 5-benzenetetraamine tetrahydrochloride (Y15) resulted in 
decreased cellular attachment and increased apoptosis in vitro, and decreased 
neuroblastoma tumor growth in vivo. These effects were more pronounced and 
sensitive in the MYCN amplified neuroblastoma cell lines [67]. Y15 is known to 
specifically and directly block phosphorylation of Y397 site of FAK in a dose and time 
dependent manner [68]. As mentioned above, Y397 is an autophosphorylation site of 
FAK and is a critical site for activating a variety of downstream targets. As a main 
phosphorylation site Y397 is also a site of binding of PI3K and Src family kinases. In 
addition, treatment of Y15 in normal ganglion cells had no effect upon the viability of 
these non-cancer cells. 
There are several FAK inhibitors currently under investigation in clinical trials. 
Recently, it has been reported that an adenosine triphosphate (ATP) competitive 
reversible inhibitor of FAK has bioavailability suitable for preclinical animal and 
human studies. PF-562271 is a diaminopyrimindine-type compound that inhibits FAK 
and exhibits high degree of selectivity in the inhibition of protein tyrosine kinases 
[69]. PF-562271 exhibited >100 fold selectivity for FAK and showed a dose-
dependent decrease in FAK phosphorylation at the Y397 site in cancer cells. PF-
562271 is currently in phase II clinical trials. In preclinical testing, PF-00562271 was 
found to slow tumor growth in prostate and glioma xenograft models and promote 
regression of bone tumors in a xenograft model of metastasis with minimal weight 
loss or mortality [69,70]. Phase I trials with thirty two patients receiving from 5 mg up 
to 105 mg twice a day of this drug in patients with advanced solid malignancy has 
been performed in two places in the United States and each one place in Canada 
and Australia. Overall, phase I trials in adult patients with solid tumors demonstrated 
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this particular drug to have good tolerability with favorable pharmacokinetics and 
pharmacodynamics and prolonged disease stabilization [71].  
 
Integrins 
Integrins are heterodimeric glycoprotein cell surface receptors comprised of α 
and β subunits and are the major metazoan mediators of cell-cell adhesions and 
cell-extracellular matrix (ECM) interactions [72]. These interactions make 
transmembrane connections to the cytoskeleton and activate multiple intracellular 
responses including adhesion and migration [73]. Additionally, ECM, which is the 
defining feature of connective tissue in animals, provides structural support to cells in 
addition to performing various other important functions such as regulating 
intercellular communication and/or cell's dynamic behavior [74]. The integrin family 
comprises of 18 α and 8 β subunits that combine to form at least 24 distinct 
heterodimers in mammals [72]. Integrins bind cell surface and ECM components 
such as collagen, fibronectin, laminin, and vitronectin, and their ligand specificity is 
determined by the specific combination of α and β subunits [75]. Integrins are known 
to participate in many aspects of tumorigenesis [76]. Although integrins alone are not 
oncogenic, recent data have shown that integrin signaling is required for some 
oncogenes to initiate their ability of tumor growth and invasion [77]. 
Aggregation of FAK with integrins and cytoskeletal proteins in focal contacts 
has been proposed to be responsible for FAK activation in cell adhesion [78]. For 
this association, the cytoplasmic domain of integrin β subunits is important [79]. 
Autophosphorylation of FAK at Y397 by integrins leads to its association with Src, 
resulting in the activation of both kinases and potential substrates, tensin, paxillin 
and p130cas [80]. A number of studies have shown that integrin signaling through 
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FAK leads to an increase in cell migration as well as potentially regulating cell 
proliferation in cancers [81,82]. 
In neuroblastoma cells, several studies were reported that integrin expression 
correlates with neuroblastoma tumorigenesis; neuroblastomas with a good prognosis 
express several integrin heterodimers, whereas those with a poor prognosis lack 
integrin expression [76,83]. Moreover, increased integrin expression resulted in 
increased neuroblastoma cell adhesion and differentiation [84]. More importantly, 
Tanaka et al. have shown that MYCN overexpression inhibits cell adhesion to the 
ECM and promotes cell migration by downregulating expression of integrin in 
neuroblastoma cells [85]. These findings suggest that MYCN may be exerting a 
negative regulatory effect on transcription of integrin, and further MYCN promotes 
metastasis by downregulating integrin, representing one mechanism that promotes 
increased neuroblastoma metastasis. Therefore, these data also suggest that 
integrin is an important regulator of neuroblastoma progression. However, it is 
unknown whether integrin expression correlates with other membrane receptors, 
specifically with GRPR signaling, and further whether there is any association 
between GRPR signaling and integrin on FAK activation thereby regulating 
neuroblastoma cell migration. My study expanded our laboratory’s investigations on 
the role of integrin expression and GRPR signaling in neuroblastoma cells by 
examining cell migration.  
Integrin targeted therapeutics using targeted antibodies for specific integrin 
subunits or heterodimers, peptide-based drugs for competing against integrin ligands 
and/or small molecule, peptidomimetic integrin inhibitors are currently under 
preclinical development and clinical evaluation for the treatment of cancer [86].  
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Role of FAK in interacting with GRP/GRPR signaling and integrins  
A large number of studies suggest that FAK is an important regulator in 
tumorigenesis and metastasis. The mechanisms by which FAK mediates the 
different processes involved in tumor progression are likely to be numerous. In the 
development of tumors, FAK overexpression seems to be important for the signal 
transduction initiated at attachment sites of cell. In fact, FAK is a key regulatory 
factor of the cell signaling cascade initiated either at the site of cell attachment or at 
growth factor receptors. FAK plays an essential role in cell adhesion and migration 
mediating the intracellular signaling of integrin receptors [87]. Cell-cell interactions 
and binding of the ECM trigger integrin clustering and the formation of focal 
adhesions within the cell. This allows bidirectional signaling across the plasma 
membrane and regulates adhesion, migration, survival, growth and differentiation in 
normal cells.  
Meanwhile, the effect of GRP/GRPR activation on tyrosine kinase cascades 
has been extensively studied in other cancers. In fact, binding of GRP to GRPR 
causes the tyrosine phosphorylation of FAK and paxillin, which links to the integrity 
of cell cytoskeleton and increases in cell motility [88]. GRPR itself does not have 
tyrosine kinase activity but interacts with G proteins, which activates downstream 
signal cascades and phosphorylates various protein substrates including FAK. 
Besides the signals from GRPR, FAK also integrates inputs from a variety of cell 
surface-associated receptors. Integrin and other growth factor receptors can 
facilitate FAK activation as measured by increased tyrosine phosphorylations at 
Y397, Y576, Y577, Y861, and Y925 to regulate cell growth, survival, and migration 
[89,90,91,92]. FAK indirectly localizes to sites of integrin clustering through C-
terminal-domain-mediated interactions [93] with integrin-associated proteins such as 
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paxillin [94,95] and talin [96]. Previous studies by others have shown that integrin and 
growth factor receptor signaling can interact through either membrane-proximal 
clustering of the two receptors or the activation of common downstream signaling 
pathways [97,98,99,100,101]. Although there is a wealth of knowledge regarding the 
signaling pathways activated by both integrin and growth factor receptors, little is 
known about how these signals are integrated by cells and whether there are 
common receptor-proximal control points that synchronize the execution of biological 
functions such as cell motility. Sieg et al. have demonstrated that FAK acts as a 
receptor-proximal bridging protein that links growth factor receptor through its N-
terminal domain and integrin through its C-terminal domain [101]. 
 
Statement of Problems and Hypothesis 
Despite advances in multi-modality treatment for pediatric solid tumors, 
patients with advanced-stage neuroblastoma, particularly in older children (> 1 yr), 
have a dismal prognosis. Novel therapeutic strategies are required to address the 
issue of tumor metastasis. Moreover, it is critical to attain a better understanding of 
the cellular and molecular mechanisms involved in neuroblastoma cell growth, 
migration, invasion and metastasis. 
Our laboratory previously reported that GRP and GRPR are overexpressed in 
aggressive neuroblastoma cell lines as well as in tumor sections from neuroblastoma 
patients when compared to benign type of cells and tissues. Further research 
demonstrated that the mitogenic effects of GRP are mediated by activation of the 
PI3K pathway followed by phosphorylation of AKT. Moreover, GRP also induces 
activation of FAK at Y397 site. The activation of FAK is involved in various 
intracellular pathways, including GRP-mediated cell signaling [102,103]. Additionally, 
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high levels of GRPR and FAK have been reported in human prostatic tissues from 
patients with advanced disease and in tumorigenic cell lines [104,105,106]. Likewise, 
many accumulating results suggest that GRP/GRPR signaling and FAK are 
associated and they contribute to tumor growth. Nevertheless, it is unknown whether 
there is a functional and physiological relationship between GRP/GRPR signaling 
and FAK, and consequently, whether GRP/GRPR regulates FAK in modulating cell 
morphology, growth, motility, and metastasis in neuroblastoma. Therefore, these 
evidences led me to hypothesize that as a critical downstream target, FAK has 
critical functions during GRP/GRPR-mediated neuroblastoma progression. 
Furthermore, I sought to determine whether GRPR interacts with integrins to 
regulate FAK activation in neuroblastoma cells, and whether there is a critical role of 
integrins to regulate cell migration in GRPR expression-modulated neuroblastoma 
cells. For this study, I investigated the expression level of FAK and GRPR in 
neuroblastoma patient samples. Moreover, I determined the role of FAK in 
GRP/GRPR-mediated neuroblastoma cell growth, migration and invasion in vitro and 
in vivo. Furthermore, I delineated the mechanism by which crosstalk between GRPR 
and integrin regulates FAK activation and metastasis. In the long term, a better 
understanding of the crosstalk between signaling pathways in neuroblastoma could 
lead to novel therapeutic strategies to be used as adjuvant treatment options in this 
clinically aggressive cancer. 
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CHAPTER II 
 
 
MATERIALS AND METHODS 
 
 
Antibodies and reagents 
Primary antibodies used include GRPR from Abcam, p-FAK, FAK and 
matrigel from BD Biosciences, MMP-2 from Calbiochem, TIMP-1 from Bethyl 
Laboratories, β-actin, Tubulin from Sigma-Aldrich, MYCN, MMP-9, p-AKT, AKT, p-
ERK1/2, ERK1/2 from Cell Signaling Technology, integrin α3 and β1 from Santa 
Cruz Biotechnology, Alexa Fluor 568 and 488 from Molecular Probes. FAK (4.47) 
antibody for immunohistochemistry was from Millipore. All secondary antibodies 
against mouse and rabbit IgG were purchased from Santa Cruz Biotechnology. GRP 
and BBS from TOCRIS Bioscience and Bachem, Y15 (C6H10N4·4ClH, 1,2,4,5-
benzenetetraamine tetrahydrochloride) from Sigma-Aldrich, and LY294002, U0126 
from Cell Signaling Technology were used. cDNA GEArray® Microarray and Flow 
Cytometric Analysis kits were obtained from SuperArray Bioscience Corporation. 
Agarose (SeaPlaque®) was from Cambrex Bio Science. Cell Counting Kit-8 (CCK-8) 
was from Dojindo Molecular Technologies. Immunohistochemistry reagents were 
from Dako Corporation. siRNAs against FAK, integrin α3 and β1 were from 
Dharmacon, along with non-targeting scrambled sequences that were used as 
controls. 
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Cell culture and transfection 
Human neuroblastoma cell lines, SK-N-SH and BE(2)-C, were purchased 
from American Type Culture Collection. Cells were maintained in RPMI 1640 media 
with L-glutamine (Cellgro Mediatech) supplemented with 10% fetal bovine serum 
(FBS; Sigma-Aldrich). Cells were maintained at 37°C in a humidified atmosphere of 
95% air and 5% CO2. Plasmids for GRPR overexpression and silencing have been 
used as previously described [44], and pCMV6-PTK2 from OriGene was used for 
transient FAK overexpression. shFAK and pCDH-FAK plasmids for in vivo study 
were kindly provided by Dr. S.T. Lim (University of South Alabama). pMSCV-LucSh, 
which contains a luciferase and zeocin-resistance fusion gene was also kindly 
provided by Dr. Andrew M. Davidoff (St. Jude Children’s Research Hospital). For 
plasmid transfection, both cell lines were transfected with Lipofectamine 2000 
(Invitrogen) according to the manufacturer’s instructions. Stably-transfected cells for 
GRPR were established by selection with G418 at 300 µg/ml and/or zeocin at 50 
µg/ml for 2 weeks. Stable populations of shFAK cells were obtained by lentiviral 
infection and puromycin selection at 2.5 µg/ml. Luciferase-expressing cells were 
established by selection with zeocin at 50 µg/ml. Cells were passed twice a week 
using trypsin 0.25% with EDTA 0.1% (Cellgro Mediatech, Inc.). GRP was 
administered after serum-starvation overnight to synchronize cells prior to 
stimulation. Cells were treated with LY294002 (20 µM), U0126 (10 µM) or Y15 (10 
µM), for 30 min prior to GRP (100 nM) stimulation for 5 min [67,107]. Experiments 
were repeated on 3 separate occasions.  
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Inducible knockdown system 
For the knockdown of our target genes, human GRP and GRPR, we used 
BLOCK-iT Inducible H1 Lentiviral RNAi System (Invitrogen). The sequence targeting 
GRPR (NM_005314) is underlined in the following shRNA (shGRPR) sequence: 5’-
CACCGTAACGTGTGCTCCAGTGGACGAATCCACTGGAGCACACGTTA-3’; the 
sequence targeting GRP (NM_002091) is underlined in the shRNA (shGRP) 
sequence: 5’-CACCAGCAATCAGCAGCCTTCGTGGGACGAATCCCACGAAGG 
CTGCTGATTGC-3’; the nonspecific control shRNA (shCON) is: 5’-
CACCGGGCGCGCTTTGT AGGATTCGCCGAAGCGAATCCTACAAAGCGCGCC-3’. 
shRNA sequences were cloned into the BLOCK-iT Inducible H1 RNAi Entry Vector 
(pENTRTM/H1/TO). Then shRNA was inserted into lentiviral vector pLenti4/BLOCK-
iT-DEST by LR recombination between pENTRTM/H1/TO entry and 
pLenti4/BLOCK-iT expression constructs. Inducible shRNA expression cells were 
established by transfecting BE(2)-C cells with both pLenti6/TR and pLenti4/BLOCK-
iT-DEST, or by introducing the vectors with the lentiviral-mediated delivery system. 
Production of lentivirus was performed in 293FT cells. Stable cell lines BE(2)-
C/tet/shCON, BE(2)-C/tet/shGRP, and BE(2)-C/tet/shGRPR were established by 
selecting with blastatin at 8 ug/ml and zerocin at 50 ug/ml post lentiviral 
transductions. 
 
Quantitative real-time PCR (QRT-PCR)  
Total RNA was isolated from neuroblastoma cells using the RNAqueousTM 
(Ambion) according to the manufacturer’s instructions. Isolated RNA (1 µg) was used 
to synthesize cDNA using the High-Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems). Primers were designed to amplify a 158-bp FAK fragment 
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(BC028733.2): forward primer 5’-TTATTGGCCACTGTGGATGA-3’; reverse primer 
5’-TACTCTTGCTGGAGGCTGGT-3’. Primers for GRPR: forward primer 5′-
ATTTGGCAGGATTGGCTGC-3′; reverse primer  5′-TGAGGCAGATCTTCATCAG-3′ 
and primers for glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as a control: 
forward primer 5′-TCCTCTGACTTCAACAGCGACACC-3′; reverse primer 5′-
TCTCTCTTCCTCTTGTGCTCTTGG-3′ were the same as published [53]. QRT-PCR 
was performed in the CFX96™ Real-Time PCR Detection Systems using SsoFast™ 
EvaGreen Supermix (Bio-Rad). The reactions were set up at 20 µl with 1 µl cDNA 
template, 10 µl Sso Fast™ EvaGreen Supermix, 1 µl of each primer (5 µmol/l), and 7 
µl distilled water. The reactions were programmed with an initial denaturation step of 
2 min at 98°C, followed by 40 temperature cycles for 5 s at 98°C and 5 s at 60°C. At 
the end of amplification, the melting curve analysis was performed for the PCR 
products to ensure the amplification specificity. All measurements were produced in 
duplicate. Relative FAK mRNA levels were calculated based on ratios of the initial 
cDNA quantity of FAK/GAPDH.  
 
Immunofluorescence  
Cells were plated onto glass coverslips in 24-well plates. The following day, 
cells were fixed with 4% paraformaldehyde for 20 min at room temperature (RT). 
After three washes with PBS, the cells were permeabilized with 0.1% Triton X-100 for 
15 min and blocked with 1% BSA/PBS for 30 min. Cells were incubated with primary 
antibodies (1:100) for 1 h at RT, washed five times with PBS and then incubated with 
secondary antibodies (1:500) for 30 min at RT. Nuclei were counterstained with 
vectashield mounting medium containing 6-diamidino-2-phenylindole (DAPI) (Vector 
Laboratories). Mouse IgG was used as a non-specific staining control, and 
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secondary antibody, without primary antibody, was used for background staining. 
The coverslips were washed with PBS five times before being mounted on 
microscope slides. Immunofluorescence signal was observed under a fluorescent 
microscope (Nikon Eclipse E600). 
 
Immunohistochemistry  
Tissues were fixed in formalin for 3 days and embedded in paraffin wax. 
Paraffin-embedded sections (5 µm) were deparaffinized in three xylene washes 
followed by a graded alcohol series, antigen retrieval performed with 10 mM sodium 
citrate buffer, and then blocked with blocking solution for 1 h at RT. Sections were 
incubated with primary antibodies overnight at 4°C, washed with PBS, incubated 
with secondary antibodies for 30 min at RT, and developed with DAB reagent. All 
sections were counterstained with hematoxylin, and then dehydrated with ethanol 
and xylene. Coverslips were mounted and slides observed by light microscopy. 
  
Immunoblotting  
Whole cell lysates were collected using cell lysis buffer (20 mM Tris, 150 mM 
NaCl, 1 mM EDTA, 1 mM EGTA, 0.1% SDS, 1% sodium deoxycholate, 1% Triton X-
100, aprotinin, leupeptin, and 1 mM sodium orthovanadate) supplemented with 
proteinase inhibitors (Roche). PMSF (1 mM) was added immediately prior to use. 
Protein (30 µg) was run on a SDS-PAGE gel, transferred onto a PVDF membrane, 
and probed with antibodies. Blots were developed using an enhanced 
chemiluminescence system (Amersham Biosciences). Image J (NIH) was used to 
perform the densitometric analysis of protein expression from immunoblots. 
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Flow cytometry 
Cells were trypsinized, washed once by adding 0.1% BSA/PBS and spun 
down. Cell pellets were resuspended in 0.1% BSA/PBS and adjusted to 1 x 106 
cells/mL. Integrin antibody (1 µg) was added to 1 mL of cell solution and incubated 
for 1 h at 4°C on a shaker, then the cells were washed with 0.1% BSA/PBS three 
time by centrifugation at 300g for 3 min. Allophycocyanin (APC)-conjugated 
secondary anti-mouse antibody (1:250) was added and incubated for 30 min at 4°C 
(excitation at 633 nm). Cells were washed three times and resuspended for flow 
cytometry analysis. Cells without primary antibody incubation was used as negative 
control. Flow cytometry was performed using a FACSCalibur System (BD 
Bioscience), and data were collected for viable cells according to side and forward 
scatter. Integrin expression on the cell surface was quantitated with fluorescence 
intensity. 
 
Cell viability assay 
Cells were seeded at a density of 3 x 103 cells/well in a 96-well plate and 
grown for up to 4 days after transfection. Cell numbers were assessed using CCK-8 
daily. Each assay was performed in triplicate, and the experiment was repeated 
three times for each cell line. The values, corresponding to the number of viable cells, 
were read at OD450 with the EL808 Ultra Microplate Reader (Bio Tek Instrument).  
 
Soft agar colony formation assay  
Cells were trypsinized and resuspended in media containing 0.4% agarose 
and 7.5% FBS and then overlaid onto a bottom layer of solidified 0.8% agarose in 5% 
serum media. SK-N-SH and BE(2)-C were plated at concentrations of 5x103 
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cells/well and 3x103 cells/well of a 12-well plate and incubated for 5 and 3 weeks, 
respectively. Colonies were stained with 0.05% Crystal Violet, photographed and 
quantified. 
 
Migration assay  
For wound healing assay, a confluent monolayer of cells in 12-well plate were 
wounded with a sterile plastic 200 µl micropipette tip. Cells in media containing 1% 
FBS for control and plus GRP (100 nM) were incubated and observed 
microscopically at 24 to 72 h. The percentage of wound filling was calculated by 
measuring the remaining gap space. For transwell migration assay, polycarbonate 
transwell filters (8 µm; Corning) were coated on the lower side with 5 µg/ml collagen 
type I (BD Biosciences) overnight and then blocked with 2.5% BSA/PBS for 1 h. 
1 × 105 cells in serum-free media added to the upper and allowed to migrate for 4 h 
at 37°C under tissue culture conditions. Cells that failed to migrate through the filter 
after incubation were scraped out using a sterile cotton swab. Cells that migrated to 
the bottom surface of the filter were fixed with 4% paraformaldehyde, stained with 
DAPI, and counted. Assay was performed in duplicates, and counting was from five 
randomly selected microscopic fields (200X magnification).  
 
In vivo assay  
Male athymic nude mice (4–6 weeks old) were maintained as described 
[108]. All studies were approved by the Institutional Animal Care and Use Committee 
at Vanderbilt University and were conducted in accordance with guidelines issued by 
the National Institutes of Health. BE(2)-C cells were transfected with luciferase alone 
or stably-transfected with plasmids (shCON, shGRPR, shFAK and/or pCDH, pCDH-
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FAK). Mice were anesthetized with isofluorane, and a small left flank incision was 
made to isolate and exteriorize the spleen; a total of 1 × 106 cells in 50 µl of Hank's 
balanced salt solution (HBSS) were injected into the splenic capsule using a 27-
gauge needle. Mice were treated daily with 50 µl of control vehicle (phosphate 
buffered saline-PBS) or Y15 (30 mg/kg/day) and/or BBS (20 µg/kg/t.i.d.). Previous 
findings with various doses and dosing schedules of the compound proved this to be 
the optimal, nontoxic dose [68,108]. Tumor growth was observed either by 
measuring luciferase signal with bioluminescence imaging system (IVIS Lumina II, 
Xenogen, Caliper Life Sciences) or by measuring body weight weekly. To perform 
tumor imaging, mice were injected with D-luciferin (OZ Biosciences) subcutaneously 
(1 mg/mouse in 100 µl of HBSS) before being anesthetized with isofluorane. 
Measurement of total flux (photons/sec) of the emitted light reflects the relative 
number of viable cells in the tumor. Data were analyzed using Xenogen Living Image 
software (version 4.1). At sacrifice, spleens and livers were excised, weighed and 
fixed in formalin for further analyses. 
 
Statistical analysis  
In vitro data represent the means ± standard deviation (SD). Statistical 
analyses were performed using a Student’s paired t-test. One-way analysis of 
variance (ANOVA) on the ranks for repeated measures was performed for multiple 
comparisons. In vivo data represent the means ± standard error of the mean (SEM). 
Tumor size and body weight were analyzed by one-way ANOVA for comparison 
among the treatment groups or Mann Whitney test with repeated measures on time. 
Data analysis was conducted using GraphPad InStat3 (GraphPad Software). For all 
experiments, a p value of < 0.05 was considered statistically significant. 
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CHAPTER III 
 
 
FAK MEDIATES GRPR-INDUCED NEUROBLASTOMA PROGRESSION 
 
 
Introduction 
 
 Neuroblastoma is highly aggressive with frequent metastases, which 
contributes to overall significant morbidity and mortality [109]. Our laboratory has 
shown that gastrin-releasing peptide receptor (GRPR), a G-protein coupled receptor, 
is involved in neuroblastoma cell survival, invasive potential and metastasis [44,110]. 
Our laboratory reported that the upregulation of GRPR increases the binding 
capacity for its ligand GRP, resulting in a faster constitutive neuroblastoma cellular 
growth rate [44]. Conversely, downregulation of GRPR reversed the aggressive cell 
phenotype and inhibited liver metastases in vivo [110]. Therefore, GRPR-mediated 
signaling plays critical roles in tumorigenesis and metastasis in neuroblastoma. 
However, we have yet to clearly define the molecular mechanisms responsible for 
GRPR-mediated tumorigenicity. 
Focal adhesion kinase (FAK), a 125-kDa cytoplasmic non-receptor protein 
tyrosine kinase, plays an essential role in cell adhesion and migration [87]. FAK is 
comprised of a central catalytic domain flanked by large N- and C-terminal non-
catalytic domains. The N-terminal domain of FAK binds to sequences in the 
cytoplasmic domain of β-integrin subunits, thereby functioning as an important 
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member of the integrin signaling pathway. The C-terminal region of FAK is rich in 
protein-protein interaction sites, directing FAK to newly-formed and existing 
adhesion complexes [87]. Cancers are known to express FAK, which is responsible 
for stimulated cell motility, invasiveness and proliferation [59,105,111]. FAK 
activation is involved in various intracellular pathways, including GRP-mediated cell 
signaling [102,103].  
High levels of GRPR and FAK have been reported in prostatic tissues from 
patients with advanced cancer and in tumorigenic cell lines [59]. One report showed 
that expression of FAK and phosphorylated (p)-FAK (Y397) correlates with the 
degree of colon cancer cell differentiation as well as to GRP/GRPR co-expression 
[112]. BBS, an amphibian equivalent of GRP, induces PC-3 cell motility through FAK 
activation [113]. Our laboratory and others have shown that GRP and BBS bind to 
GRPR with high affinity to stimulate neuroblastoma cell growth in an autocrine 
and/or paracrine fashion [43,113]. However, the intracellular signaling mechanisms 
involved in GRP/GRPR-mediated FAK activation and subsequent neuroblastoma 
cell growth, motility and metastasis remain unclear. 
 
 
Results 
 
GRPR and FAK correlated with malignant potential of neuroblastoma. 
Our laboratory reported that an increased GRP and GRPR expression is 
found in more undifferentiated neuroblastoma [43]. FAK expression has been 
correlated with advanced-stage neuroblastoma [24]. In this study, we wanted to 
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determine whether GRPR expression is associated with FAK in neuroblastoma. 
Firstly, I performed immunohistochemistry to assess GRPR and FAK expression in 
seven paraffin-embedded tumor sections consisting of five undifferentiated 
neuroblastomas and two ganglioneuromas. As expected, increased FAK expression 
was noted in undifferentiated neuroblastomas when compared to more benign 
phenotype of ganglioneuromas; its expression also correlated with GRPR (Fig. 3A). 
But due to the limited sample size, I could not determine a correlation of these two 
protein markers with clinical disease staging. Next, when grown on soft agar, BE(2)-
C cells exhibited significantly more colony formation (Fig. 3B), which indicates 
malignant potential. Consistent with GRPR protein levels, we found higher levels of 
FAK protein (Fig. 3B) as well as mRNA (Fig. 3C) in BE(2)-C when compared to SK-
N-SH cells. Immunofluorescence also demonstrated that BE(2)-C cells show more 
intense GRPR and FAK expression when compared to SK-N-SH cells (Fig. 3D). 
These results show that FAK expression correlates with malignant potential induced 
by increased GRPR expression in neuroblastoma. 
 
GRP induced FAK activation (Y397) and cell migration in BE(2)-C cells.  
FAK activation at Y397 site by GRP is well established in 293 HEK cells and 
various other cancer types [102,113,114]. When GRP was exogenously 
administered for 5 min, an increase in p-FAK (Y397) was noted in a dose-dependent 
manner in BE(2)-C cells, whereas SK-N-SH cells did not (Fig. 4A). Moreover, I also 
found that GRP treatment induces significant BE(2)-C cell migration in both transwell 
migration assay and wound healing assay (Fig. 4B, C). This results support for the 
important role of FAK as a mediator of GRP/GRPR signaling, and further validate 
GRP as an inducer of cell migration in neuroblastoma.   
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Figure 3. GRPR and FAK expressions correlate to neuroblastoma malignancy. (A) 
Representative histological sections from human ganglioneuroma and undifferentiated 
neuroblastomas showed similar FAK (top row) and GRPR (bottom row) expressions by 
immunohistochemistry (100X magnification, 20 µm bar). (B) Increased number of colony 
formation was observed in BE(2)-C cells. BE(2)-C cells demonstrated higher constitutive 
GRPR and FAK protein levels when compared to SK-N-SH cells by immunoblotting. β-
actin showed relatively equal loading. (C) A higher basal level of FAK mRNA was also 
observed in BE(2)-C cells. FAK mRNA level was expressed as relative copies of 
FAK/GAPDH. Bars represent the averages of three independent experiments. (*= p 
<0.05 vs. BE(2)-C). (D) More intense immunofluorescence of FAK and GRPR were 
observed in BE(2)-C cells when compared to SK-N-SH cells (600X magnification).   
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Figure 4. GRP induces FAK activation (Y397) and migration. (A) Exogenous GRP for 
5 min after overnight serum starvation increased p-FAK (Y397) as measured by 
immunoblotting; increased p-FAK by 10 nM and 100 nM of GRP in BE(2)-C was 
observed when compared to SK-N-SH cells (*= p <0.05 vs. no treated control). (B) GRP-
stimulated cell migration was performed using transwell plates in BE(E)-C cells. Values 
are expressed using migrated cell numbers from two experiments performed in 
duplicate. Representative images of DAPI staining for counting were shown (200X 
magnification) (*= p <0.05 vs. CON). (C) Wound closure was measured from 
microscopic images at 24, 48, and 72 h after wounding (100X magnification). Data are 
representative of the mean distance of unclosure from three independent experiments 
(*= p <0.05 vs. CON).  
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GRPR overexpression increased FAK and integrins expression, which promoted cell 
migration in SK-N-SH cells.   
To understand the positive relationship between FAK and GRPR in 
neuroblastoma cells, we next performed studies using a GRPR overexpressing SK-
N-SH cell line established in our laboratory [44]. In figure 5A, GRPR overexpressing 
SK-N-SH cells showed increased GRPR mRNA expression but no significant 
increase of FAK mRNA (*= p <0.05 vs. SK/CON). However, immunoblotting showed 
that FAK protein is upregulated in GRPR overexpressing SK-N-SH cells when 
compared to controls (Fig. 5B). Interestingly, integrin α3 and β1 expressions were 
also significantly upregulated in GRPR overexpressing cells (Fig. 5B). To confirm 
whether increased FAK activation in GRPR overexpressing cells is dependent on 
these upregualted integrin expressions, I next performed dual silencing of integrin α3 
and β1 (siIntegrin α3β1) in GRPR overexpressing SK-N-SH cells and found that 
siIntegrin α3β1 significantly decreased p-FAK expression (Fig. 5C). Additionally, to 
validate these findings and to localize FAK expression, I next performed 
immunofluorescence study. GRPR overexpressing SK-N-SH cells, which have an 
altered cell morphology exhibiting a flatter shape with broad lamellipodial projections, 
showed significantly enhanced FAK expression at the leading edges of cells (Fig. 
5D). Furthermore, GRPR overexpressing SK-N-SH cells exhibited increased cell 
migration in the transwell plates coated with collagen type I (Fig. 5E). These results 
indicate that GRPR regulates FAK levels post-transcriptionally and FAK activation is 
regulated in part by integrin expressions in GRPR overexpressing SK-N-SH cells. 
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Figure 5. GRPR overexpression increases FAK and cell migration in SK-N-SH cells. 
(A) Increased levels of GRPR mRNA but no significant increase of FAK mRNA were 
observed in GRPR overexpressing SK-N-SH cells. Bars represent the averages of three 
independent experiments. (*= p <0.05 vs. SK/CON). (B) Increased FAK expression as 
well as integrin α3 and β1 levels in GRPR overexpressing SK-N-SH cells were 
confirmed by immunoblotting. β-actin demonstrated relatively equal loading. (C) Dual 
silencing of integrin α3 and β1 (siIntegrin α3β1) in GRPR overexpressing SK-N-SH cells 
decreased expression of p-FAK (Y397). β-actin demonstrated relatively equal loading. 
(D) GRPR overexpressing SK-N-SH cells demonstrated altered cellular morphology to a 
flatter appearance along with significantly more intense FAK immunofluorescence (red 
color). Merged image indicates FAK, Tubulin (green color) and nuclei (400X 
magnification). A representative higher magnification image (enlarged box) showed 
intense FAK localization at the leading edges. (E) GRPR overexpressing SK-N-SH cells 
migrated more in collagen type I-coated transwell plates when compared to the control. 
Values are expressed using migrated cell numbers from two experiments performed in 
duplicate. Representative images of DAPI staining for counting were shown (200X 
magnification) (*= p <0.05 vs. CON). 
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GRPR silencing decreased FAK and cell migration in BE(2)-C cells.  
Next, to further validate the correlation between GRPR and FAK, I used 
stably-transfected GRPR silenced BE(2)-C cells (shGRPR) established in our 
laboratory [110]. In figure 6A, GRPR silenced BE(2)-C cells showed decreases in 
both GRPR as well as FAK mRNA levels (*= p <0.05 vs. BE/shCON). Furthermore, I 
found that both phosphorylated and total FAK protein levels were decreased in 
shGRPR (Fig. 6B). Interestingly, I also found that shGRPR cells downregulated 
MYCN (Fig. 6B), which is a well-known transcription factor of FAK in neuroblastoma 
[115,116]. Consistent with these findings, immunofluorescence showed significantly  
weaker FAK expression in shGRPR when compared to control cells (shCON) (Fig. 
6C). Moreover, the appearance of BE(2)-C cells changed from typical flat and 
aggregated morphology to small and rounder shape after transfection with silencing 
of GRPR. Furthermore, shGRPR cells exhibited decreased cell migration in the 
transwell plates coated with collagen type I (Fig. 6D). Hence, my results support a 
positive correlation between GRPR and FAK, indicating that GRPR is important for a 
cellular function of cell morphology and migration in neuroblastoma cells by 
regulating FAK. 
 
Downregulation of GRP/GRPR reduced expression of MYCN. 
MYCN, a strong predictor of poor outcomes in patients with neuroblastoma, is 
a downstream target of PI3K/AKT pathway [21,117,118]. Our laboratory has 
previously reported that MYCN mediated PI3K-dependent regulation of VEGF 
expression in neuroblastoma cells [21]. Recent study further demonstrated that anti-
angiogenic efficacy of NVP-BEZ235, which is a dual inhibitor of PI3K and mTOR, 
depended critically on MYCN in vitro and in vivo [119]. Interestingly, our laboratory’s 
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Figure 6. GRPR silencing decreases FAK and cell migration in BE(2)-C cells. (A) 
Decreases in both GRPR mRNA as well as FAK mRNA expression were in GRPR 
silenced BE(2)-C cells. Bars represent the averages of three independent experiments. 
(*= p <0.05 vs. shCON). (B) Decreased FAK and MYCN expressions in GRPR silenced 
BE(2)-C cells (shGRPR) was confirmed by immunoblotting. β-actin demonstrated 
relatively equal loading. (C) shGRPR demonstrated a rounder, smaller morphology and 
showed weaker FAK immunofluorescence (red color) when compared to control cells 
(shCON). Merged image indicates FAK and nuclei (400X magnification). (D) shGRPR 
migrated less in collagen type I-coated transwell plates when compared to shCON. 
Values are expressed using migrated cell numbers from two experiments performed in 
duplicate. Representative images of DAPI staining for counting were shown (200X 
magnification) (*= p <0.05 vs. shCON). 
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previous study demonstrated that GRPR is an important regulator for neuroblastoma 
progression and metastasis, and that the PI3K pathway is significantly 
downregulated in GRPR silenced BE(2)-C cells [110]. We examined whether 
GRP/GRPR signaling regulates MYCN expression in MYCN-amplified BE(2)-C cells. 
In order to exclude the effects of MYCN expression by cell cycle, the cells were 
synchronized by serum-starvation for 24 h, then re-fed in RPMI medium with 10% 
FBS. The expression of MYCN proteins in GRPR silenced BE(2)-C cells was 
significantly decreased in comparison to shCON cells at 0 h, and completely 
degraded after 2 h (Fig. 7A). However, the mRNA levels of MYCN, as measured by 
QRT-PCR, were not appreciably affected by GRPR silencing (Fig. 7B). Our results 
suggest that GRPR activation of cell signaling regulates endogenous MYCN 
expression at a post-transcriptional level. In order to exclude any specific effect of 
stable GRPR silencing, we also used a doxycycline-inducible silencing system in 
BE(2)-C cells (Tet/shGRPR), in which GRPR can be conditionally downregulated by 
doxycycline treatment. MYCN expression was significantly decreased in a dose-
dependent manner after doxycycline-induced GRPR silencing (Fig. 7C). Furthermore, 
using another doxycycline-inducible system for silencing GRP (Tet/shGRP), we 
assessed the exact effects of GRP silencing on MYCN expression in BE(2)-C cells. 
This demonstrated similar results to the shGRPR inducible system, in which MYCN 
expression decreased following doxycycline treatment for 48 h (Fig. 7D). Hence, this 
finding indicate that GRP/GRPR signaling regulates MYCN expression, which may 
be at a post-transcriptional level in neuroblastoma cells.  
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Figure 7. GRP/GRPR regulates MYCN expression. (A) MYCN expression was 
measured in control and GRPR silenced BE(2)-C cells by Western blotting. Cells were 
serum-starved for 24 h and were then re-plated in fresh RPMI media with 10% FBS. As 
expected, GRPR expression lower in shGRPR cells than in shCON cells. Interestingly, 
MYCN expression was decreased in shGRPR cells at 0 and 2 h. (B) Cells were serum-
starved for 24 h, and then total RNA was extracted for real-time QRT-PCR at 24 h 
transfections. MYCN mRNA levels remained relatively unchanged. Bars represent the 
averages of three independent experiments. (C) Inducible GRPR silencing BE(2)-
C/Tet/shGRPR cells were treated with doxycyclin for  48 h, and then the expression of 
MYCN were analyzed by Western blotting. MYCN expression level was correspondingly 
decreased with GRPR silencing (4C, left); Decreased GRPR mRNA was confirmed with 
RT-PCR (4C, right). (D) Similar to Fig. 4C, inducible GRP silencing BE(2)-C/Tet/shGRP 
cells were treated with doxycyclin for 48 h. The expression of MYCN was confirmed with 
Western blotting (4D, left). Inducible knockdown of GRP mRNA was confirmed with RT-
PCR (4D, right). Levels of protein expression were quantified by densitometry analysis 
and the values were labeled under the bands. 
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FAK regulated neuroblastoma cell growth in vitro and in vivo.  
In order to examine the critical role of FAK on neuroblastoma malignant 
potential, I transiently transfected SK-N-SH and BE(2)-C cells with FAK plasmid (Fig. 
8A) and siRNA against FAK (siFAK) (Fig. 9A, B), respectively. To validate the effects 
of downstream signaling pathways on modulating FAK expression in each cell line, 
phosphorylated and total expressions of AKT and extracellular signal-regulated 
protein kinases 1 and 2 (ERK1/2) were examined. Interestingly, modulation of FAK 
expression led to differential expression of p-AKT and p-ERK (Figs. 8A, 9B). FAK 
overexpression stimulated phosphorylation of AKT and ERK. Conversely, FAK 
silencing decreased p-AKT and p-ERK levels, hence suggesting a mechanism of 
FAK activation of PI3K and MEK pathways in neuroblastoma cells. I used soft agar 
colony assay to assess for anchorage-independent cell growth, which is a well-
established indicator of tumorigenicity of cancer cells in vitro [120]. FAK 
overexpression showed an increased number of colonies by > 2.5-fold, and quite 
interestingly, it also resulted in formation of larger colonies (Fig. 8B). Furthermore, 
cell viability also increased over a time course with most significant increase at 96 h 
(Fig. 8C). In contrast, siFAK showed decreased number of colonies by 35%; siFAK 
resulted in fewer and smaller colonies when compared to non-targeting control 
siRNA (siNTC) (Fig. 9C). siFAK also significantly decreased BE(2)-C cell viability 
(Fig. 9D). To validate these findings in vivo and to further examine the metastatic 
potential of BE(2)-C cells stably-transfected with shRNA against either control 
(shCON) or FAK (shFAK), I performed intrasplenic injections of neuroblastoma cells 
in nude mice. Our laboratory established the murine model to investigate 
neuroblastoma metastasis, and reported that GRPR silencing inhibited tumor growth  
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Figure 8. FAK overexpression upregulates SK-N-SH neuroblastoma cell growth. (A) 
Immunoblotting demonstrated FAK overexpression in SK-N-SH cells. pCMV6-XL4 was 
used for control. Phosphorylated and total protein levels of AKT and ERK1/2 were tested 
in the cells. β-actin demonstrated relatively equal loading. (B) FAK overexpression 
increased soft agar colonies by nearly 2.5-fold (*= p <0.05 vs. CON). (C) FAK 
overexpression increased SK-N-SH cell viability after 72 h. Bars represent the averages 
of three independent experiments. (*= p <0.05 vs. CON).  
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Figure 9. FAK silencing inhibits BE(2)-C neuroblastoma cell growth in vitro and in 
vivo. (A) Cells after 48h transfection of siRNA against FAK. (B) Immunoblotting 
demonstrated transient FAK silencing (siFAK) in BE(2)-C cells. siFAK decreased 
phosphorylated protein levels of AKT and ERK1/2. β-actin demonstrated relatively equal 
loading. (C) siFAK inhibited colony formation by 35% compared to control (siNTC) (*= p 
<0.05 vs. siNTC). (D) siFAK significantly inhibited BE(2)-C cell viability after 48 h. Bars 
represent the averages of three independent experiments. (*= p <0.05 vs. siNTC). (E) 
Immunoblotting demonstrated stable FAK silencing (shFAK) in BE(2)-C cells. β-actin 
demonstrated relatively equal loading. (F) Representative gross images of tumor from 
mice and H&E staining of liver sections (200X magnification, 50 µm bar) (G) Spleen and 
liver weight relative to body weight (n = 6 mice in each group; **= p <0.005 vs. shCON; 
Mann Whitney test).   
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and liver metastases in vivo [110]. Specificity of FAK silencing was demonstrated by 
immunoblotting (Fig. 9E). Six weeks after injections, tumor volume of spleens and 
livers were examined. While shCON formed numerous large liver metastases, 
shFAK developed very few liver lesions (Fig. 9F). The average spleen and liver 
weight in the shFAK group was approximately 62% of the shCON group (mean value 
0.08 for shCON vs. 0.05 for shFAK) (Fig. 9G). These results indicate that FAK 
silencing decreases malignant potential of neuroblastoma cells, thus providing 
further support for the importance of FAK as a regulator of neuroblastoma 
malignancy.  
 
FAK overexpression rescued GRPR silencing-mediated inhibition of cell growth in 
vitro and in vivo. 
To assess whether FAK is a downstream target of GRPR-mediated cell 
signaling, I next performed rescue experiments using a FAK plasmid in shGRPR 
cells in order to test whether FAK overexpression recovers the inhibitory effect of 
shGRPR. Immunoblotting showed knockdown of GRPR and overexpression of FAK 
after transfections (Fig. 10A). As previously reported [110], shGRPR exhibited 
significantly reduced number of soft agar colony formation. FAK overexpression 
resulted in increased colony formation in both shCON and shGRPR cells (Fig. 10B). 
FAK overexpression in shGRPR cells rescued their ability to form colonies to a 
similar value to that of shCON. Correlative to soft agar colony formation, cell viability 
assays demonstrated restored cell growth after FAK overexpression in shGRPR 
cells (Fig. 10C). Furthermore, to demonstrate these observations in vivo, I used a 
murine model after stably-transfecting BE(2)-C cells with a lentiviral system of FAK  
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Figure 10. FAK overexpression in GRPR silencing restores neuroblastoma growth. 
(A) Immunoblotting confirmed transient FAK overexpression (pCMV6-PTK2) in shGRPR. 
β-actin demonstrated relatively equal loading. (B) FAK overexpression increased soft 
agar colonies in shCON and shGRPR when compared to controls of FAK 
overexpression (*= p <0.05 vs. FAK vector control). (C) FAK overexpression in shGRPR 
restored cell viability. Bars represent the averages of three independent experiments. (*= 
p <0.05 vs. FAK vector control). (D) Immunoblotting confirmed stable FAK 
overexpression (pCDH-FAK) in shGRPR. β-actin demonstrated relatively equal loading. 
(E) Representative gross images of tumor from mice (shCON/pCDH = CC, 
shGRPR/pCDH = GC, shGRPR/pCDH-FAK = GF, shGRPR/pCDH-GRPR = GG) and 
H&E staining of liver sections (200X magnification, 50 µm bar) (F) Spleen and liver 
weight relative to body weight (n = 4-5 mice in each group; *= p <0.05 vs. CC, †= p 
<0.05 vs. GC; Mann Whitney test). 
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plasmid. Specificity of each protein expression was demonstrated by immunoblotting 
(Fig. 10D). BE(2)-C cells with GRPR knockdown (GC) induced fewer metastatic 
lesions in the liver when compared to control (CC), and reintroducing GRPR (GG) 
into cells rescued the inhibitory effect of GC (Fig. 10E). Although FAK 
overexpression in GC did not show statistically significant effects on liver metastasis, 
the mean weight of spleen and liver in these mice increased by ~1.5-fold of GC 
(mean value 0.06 for GC vs. 0.09 for GF) (Fig. 10F). These findings suggest that 
FAK plays a critical role in GRPR-induced anchorage-independent growth, and as a 
downstream target of GRPR, FAK expression, in part, compensates for the inhibitory 
effect of GRPR silencing in neuroblastoma. Taken together, my results demonstrate 
that FAK is an important mediator in the GRP/GRPR signaling pathway. 
 
FAK inhibition reduced GRP-induced colony growth and cell migration in vitro.  
Previously, our laboratory has demonstrated that GRP treatment activated 
PI3K by showing the increase of phosphorylation of AKT and GSK3α/β, downstream 
effectors for the PI3K pathway [107]. Moreover, the activation at Y397 of FAK by 
GRP treatment has been reported by many other studies. In order to examine the 
effect of FAK inhibition on GRP-induced activation of downstream signal pathway, I 
performed combination treatment in soft agar colony formation and migration assay. 
First of all, I found that pre-treatment with Y15 compound (10 µM), a FAK-specific 
inhibitor, for 30 min failed to induce FAK activation by GRP for 5 min after overnight 
serum starvation at Y397 in BE(2)-C cells (Fig. 11A). GRP alone induced activation 
of AKT and ERK1/2, whereas Y15 treatment attenuated GRP-induced increases in 
p-AKT and p-ERK (Fig. 11A). Additionally, I found that pretreatment of PI3K-specific 
inhibitor (LY249002) or ERK-specific inhibitor (U0126) did not block FAK activation  
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Figure 11. Y15, a FAK inhibitor blocks GRP-induced neuroblastoma growth in vitro. 
(A) Immunoblotting confirmed that GRP-induced FAK activation in BE(2)-C cells was 
blocked by pre-treatment of Y15 (10 µM) for 30 min. Y15 treatment attenuated GRP-
induced activation of AKT and ERK1/2. (B) GRP (100 nM) increased colony formation by 
~1.2-fold whereas Y15 (10 µM) inhibited it by 45% compared to control; similarly Y15 
also inhibited GRP-induced colony formation. Bars represent the averages of three 
independent experiments. (*= p <0.05 vs. CON, †= p <0.05 vs. GRP). GRP and Y15 
were added into serum media on solidified soft agar.  
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Figure 12. FAK activation by GRP treatment combined with other inhibitors. GRP 
plus LY249002 (A) or U0126 (B) induced phosphorylation of FAK (Y397). Neither 
LY249002 nor U0126 altered GRP-induced phosphorylation of FAK (Y397). 
Immunoblotting confirmed the specific inhibitory effects of LY249002 or U0126 on AKT 
and ERK, respectively. Cells were pretreated with each inhibitor for 30 min after 
overnight serum starvation, and stimulated with GRP (100 nM) for 5 min.  
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Figure 13. FAK silencing decreases GRP-induced neuroblastoma cell migration. (A) 
Representative images of DAPI staining for counting were shown (200X magnification). 
(B) GRP-stimulated cell migration in siNTC and siFAK was performed using transwell 
plates in BE(E)-C cells. siFAK inhibited cell migration by 40% compared to siNTC. GRP 
(100 nM) increased cell migration by ~1.2-fold in siNTC cells whereas GRP did not 
induce cell migration in siFAK cells (*= p <0.05 vs. siNTC, †= p <0.05 vs. siNTC+GRP). 
GRP were added into the bottom well of transwell plates. Values are expressed using 
migrated cell numbers from two experiments performed in duplicate.  
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at Y397 when GRP was treated following those inhibitors (Fig. 12A, B). These data 
suggest that FAK activation by GRP is independent of AKT and ERK pathways, and 
further it indicates that FAK is upstream target of AKT and ERK. Interestingly, I also 
found that the Y15 treatment also significantly inhibited GRP-induced colony 
formation in soft agar by > 2-fold (Fig. 11B). Furthermore, GRP did not induce 
increased cell migration when FAK was downregulated by siRNA against FAK (Fig. 
13 A, B). These findings strongly suggest that FAK is a critical mediator of GRP-
induced neuroblastoma cell growth and migration. FAK inhibition by either a 
compound or an antisense oligonucleotide can effectively block GRP stimulation in 
neuroblastoma cells. 
 
FAK inhibition reduced BBS-induced tumor growth and metastasis in vivo.  
Previously, our laboratory has reported that BBS, an amphibian equivalent of 
GRP, promotes neuroblastoma tumor growth in vivo, and is an important stimulator 
of angiogenic pathway [21,108]. Additionally, Y15 has shown to decrease 
neuroblastoma growth in vivo [67,68]. Based on all these findings, I wanted to 
determine whether FAK inhibition could block BBS-induced tumor growth and 
metastases in vivo. 1 × 106 of luciferase-expressing BE(2)-C cells were injected into 
spleen in athymic nude mice. After three days, they were randomized into four 
groups: control (PBS vehicle), BBS (20 µg/kg/i.p./t.i.d.), Y15 (30 mg/kg/i.p./day), and 
BBS plus Y15. Bioluminescence imaging system was used to monitor for primary 
tumor growth in spleen as well as liver metastasis. As shown in Figure 14A, signals 
exhibited relatively equal intensities on day 1; however, by day 20, BBS significantly 
increased primary splenic tumor growth as well as liver metastases while a 
combination treatment with Y15 showed remarkable reduction in tumor growth and  
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Figure 14. Y15 blocks BBS-induced neuroblastoma growth and metastasis in vivo. 
(A) Bioluminescence images showing luciferase-expressing BE(2)-C cells in an 
intrasplenic injection murine model. Pseudocolor images from each group were adjusted 
to the same threshold of the day. At day 1, mice were imaged on their left side to detect 
relatively equal intensity of luminescent signal of spleen. At day 20, BBS (20 
µg/kg/i.p./t.i.d.) promoted tumor growth and liver metastases, whereas Y15 (30 
mg/kg/i.p./day) showed the opposite effect, and further inhibited BBS-induced tumor 
growth and liver metastases. (B) Quantitative values of bioluminescence were measured 
as photon counts. Results were given as the mean ± SEM (n = 5-6 mice in each group; 
*= p <0.05 vs. CON, †= p <0.05 vs. BBS). (C) Representative bioluminescence images 
of tumor tissue extracted from the mice of each group and representative images of H&E 
staining to confirm metastatic foci of neuroblastoma cells in liver lesions (200X 
magnification, 50 µm bar) (D) Spleen and liver weight relative to body weight (n = 5-6 
mice in each group; *= p <0.05 vs. CON, †= p <0.05 vs. BBS; Mann Whitney test).  
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metastases. The inhibitory effects of Y15 in BBS-induced tumor growth were 
confirmed by luciferase activity of luciferase-expressing BE(2)-C cells (Fig. 14A, B) 
as well as by spleen and liver weight (Fig. 14C, D). Differences in luciferase activity 
at day 20 correlated with tumor weights in the liver and spleen. BBS increased 
luciferase activity by > 80-fold as compared to controls (mean activity 5.30 × 107 
photons/s for controls vs. 4.27 × 109 photons/s for BBS) whereas Y15 decreased the 
activity by < 110-fold as compared to controls (mean activity 5.30 × 107 photons/s for 
controls vs. 4.78 × 105 photons/s for Y15). More importantly, BBS plus Y15 
combination significantly reduced luciferase activity when compared to BBS alone 
(mean activity 4.27 × 109 photons/s for BBS vs. 2.65 × 105 photons/s for BBS plus 
Y15). Thus, our in vivo data corroborate in vitro findings, and further suggest that 
FAK is an important regulator of the GRP/GRPR signaling pathway and tumor 
metastasis in neuroblastoma.  
In this study, I showed that GRPR and FAK expressions in human 
neuroblastoma tissues and cell lines correlate with tumor malignancy. Exogenous 
GRP induced FAK activation at Y397 and enhanced cell migration. Interestingly, 
GRPR overexpression increased FAK, integrin expressions as well as cell migration 
in SK-N-SH cells. Conversely, GRPR silencing resulted in decreased FAK and 
MYCN proteins in BE(2)-C cells while FAK overexpression in GRPR silenced BE(2)-
C cells rescued cell growth. Moreover, FAK overexpression alone led to an increase 
in soft agar colony formation in SK-N-SH cells, whereas FAK silencing resulted in 
decreased colony formation in BE(2)-C cells. I also found that FAK silencing in 
BE(2)-C cells suppressed tumorigenesis and metastasis in vivo. Furthermore, using 
an intrasplenic murine model and bioluminescence imaging system, I confirmed that 
treatment with Y15, a FAK inhibitor, blocks BBS-induced neuroblastoma growth and 
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liver metastases in vivo. My results demonstrated that FAK correlates with GRPR, 
and that it exerts oncogenic effects in neuroblastoma as a mediator of GRPR 
signaling pathway. Hence, FAK may be a clinically important therapeutic target in the 
treatment of neuroblastomas. 
 
 
Discussion 
 
Our laboratory previously demonstrated that GRPR is overexpressed in 
malignant, advanced-stage neuroblastomas, and that GRPR silencing suppresses 
tumorigenesis and metastasis in vivo [43,110]. However, the exact molecular 
mechanisms of GPR/GRPR regulation of tumor progression are yet to be delineated. 
In this study, I provide compelling evidence from cell and animal studies that FAK is 
an important mediator of GRP/GRPR signaling-induced neuroblastoma growth and 
metastasis. I investigated the relationship between GRPR and FAK, as well as the 
effect of FAK silencing using transfected cells and/or a pharmacologic agent on 
tumor growth in vitro and in vivo. GRP/GRPR regulated FAK activation and 
expression, and further inhibition of FAK repressed GRP/GRPR signaling involved in 
neuroblastoma progression. These results suggested that FAK is a critical 
downstream target of GRP/GRPR, and therefore may be a promising therapeutic 
target for malignant neuroblastomas.  
GRP, the mammalian analogue of BBS, is a growth factor that promotes cell 
proliferation in cancer cells [30,33]. Specifically, GRP induces activation of FAK at 
Y397 site, which is known to be critical for promoting both integrin- and/or growth 
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factor- stimulated cell migration, and is a high-affinity binding site for Src homology 2 
(SH2) of the Src family kinases [121], which creates the possibility for interaction 
with a number of different signaling and adaptor proteins. In the present study, I 
found that GRP/GRPR signaling regulates FAK activation and expression. I also 
found that GRPR expression correlates with integrin expressions. Thus, our findings 
further support published results that integrin and growth factor receptor signaling 
can interact through either membrane-proximal clustering of the two receptor types 
or the activation of common downstream signaling pathways [98,101].  
Our findings corroborate the multiple tumorigenic functions of FAK, which are 
associated with various malignant and aggressive tumors, including ductal 
carcinomas of the breast [122], primary colorectal tumors and metastases [123], and 
endometrial carcinomas [124]. FAK has been used as a prognostic indicator as well 
as a marker for malignant transformation in breast carcinoma [125]. Additionally, 
FAK has been established as a significant component in the BBS signaling pathways 
in prostate cancer [102,103,113] and described to play a critical role in GRP-
mediated morphogenesis of colon cancer [114]. Glover et al. [102] showed that the 
FAK Y397 site is critical for GRP-induced morphogenesis in 293 HEK cells, and we 
have shown that BBS promotes tumor growth and angiogenesis in neuroblastoma in 
vivo [21,108]. Here, I show that GRP or BBS stimulates neuroblastoma cell migration 
as well as liver metastases, further supporting a critical tumorigenic role of GRP or 
BBS in neuroblastoma. More importantly, our results, for the first time, show that 
FAK inhibition is critical to block BBS-induced tumorigenesis and metastasis in vivo, 
and thus, further indicating FAK as an important therapeutic target in the treatment 
of neuroblastomas.  
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Y15 compound, 1,2,4,5-benzenetetraamine tetrahydrochloride, has been 
shown to block phosphorylation of FAK at Y397 in neuroblastoma cell lines as well 
as inhibit growth of MYCN-amplified neuroblastoma tumors in vivo [67]. In my study, 
we used MYCN-amplified I-type BE(2)-C and MYCN single copy N-type SK-N-SH 
neuroblastoma cell lines. Since, MYCN regulates FAK expression at the promoter 
level in neuroblastoma cells [25], I speculated that GRPR signaling would affect FAK 
by regulating MYCN. This is supported by the results that showed reduced level of 
FAK mRNA in GRPR silenced BE(2)-C cells. However, the molecular mechanism of 
GRP/GRPR signaling-dependent regulation of MYCN and subsequently FAK in 
MYCN-amplified neuroblastoma cells or MYCN single copy neuroblastoma cells 
remain to be defined. 
Our laboratory previously reported that the aberrant activation of PI3K/AKT 
pathway regulates GRP/GRPR-mediated oncogenic functions [43,44,107,110]. We 
specifically found that of all three AKT isoforms, only AKT2 was downregulated with 
GRPR silencing in neuroblastoma cells [110]. Specifically, AKT2 silencing decreased 
MYCN expression, anchorage-independent cell growth, and liver metastases in vivo. 
Conversely, exogenously overexpression of AKT2 increased MYCN expression in 
BE(2)-C cells (data not shown here). Of the three AKT isoforms, AKT2 has been 
implicated more frequently in numerous cancers [126,127,128]. Consistent with 
other cancer cell types, our data showed that AKT2 is the most critical isoform 
responsible for progression of neuroblastoma. Therefore, we believe that activation 
of AKT signaling is critical for GRPR-mediated regulation on MYCN expression, 
which might be through post-transcriptional modulation of the stability of MYCN in 
neuroblastoma cells. A recent study has shown that MYCN contributes to 
tumorigenesis, in part, by repressing miR-184, and increasing AKT2 expression, a 
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direct target of miR-184 [129], and thereby indicating that AKT2 is a downstream 
target of MYCN. Taken together, it suggests that a positive regulatory loop exists 
between two oncogenic proteins, AKT signaling and MYCN in human neuroblastoma 
cells, which contributes crucially to the development of tumorigenicity. Collectively, 
we think that there is a GRPR/AKT/MYCN axis and in this study, I showed that 
GRPR silencing decreases MYCN expression, which affects on FAK expression in 
MYCN-amplified human neuroblastoma cells.  
Tilghman et al. [130] noted that loss of FAK results in marked changes in cell 
morphology and defects in leading edge formation. Similar to their findings, I also 
found that silencing of FAK by either cell transfection or chemical compound induced 
morphological changes analogous to the effects of silencing of GRPR, and further 
inhibited colony formation. Hence, I infer that GRPR and FAK are essential for 
regulating cell morphology, which can associate with the oncogenic properties such 
as highly migratory, anchorage-independent phenotype in neuroblastoma. Therefore, 
a better understanding of GRPR and FAK regulation may not only be of biological 
significance, but may also provide a molecular basis for potential clinical applications. 
In conclusion, my study demonstrates that FAK is a crucial regulator of 
GRP/GRPR signaling in neuroblastoma. GRP/GRPR regulates neuroblastoma cell 
growth, transformation and migration by correlative regulation of FAK. Furthermore, 
my results suggest that targeting FAK can inhibit GRP/GRPR-mediated oncogenic 
properties. Moreover, this study demonstrates the roles of FAK in neuroblastoma 
tumorigenesis and metastasis in vitro and in vivo. These findings are clinically 
relevant because advanced-stage neuroblastoma is oftentimes refractory to current 
multi-modality treatment protocols, and effective novel therapeutic target(s) are 
highly desirable. Hence, a better understanding of the mechanisms involved in 
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GRPR/FAK-induced metastatic potential could provide insights into development of 
novel strategies in the treatment of aggressive, undifferentiated neuroblastoma. 
 
 
Most data shown in this chapter were published in Oncotarget. 2012 
Dec;3(12):1576-87. FAK is a critical regulator of neuroblastoma liver metastasis. Lee 
S, Qiao J, Paul P, O'Connor KL, Evers BM, Chung DH [131].     
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CHAPTER IV 
 
 
INTEGRIN β1 PLAYS A ROLE IN GRP/GRPR-INDUCED CELL MIGRATION 
 
 
Introduction 
 
Neuroblastoma, a neural crest cell-derived tumor, is the most common extra-
cranial solid tumor of infants and children, accounting for approximately 10% of all 
childhood-related death. [132]. Since roughly 50% of patients will have metastatic 
disease at the time of diagnosis [133], there have been considerable efforts aimed at 
delineating the cellular mechanisms that contribute to metastatic progression in 
neuroblastoma, leading to poor overall survival. Clinicopathologic data has shown 
that age greater than 12 months at diagnosis, MYCN amplification, unfavorable 
tumor histopathologic evaluation, and the presence of systemic metastatic disease 
are factors that portend a ‘high-risk’ classification and are each associated with poor 
prognosis [134]. The poor survival seen in patients with metastatic or refractory 
neuroblastoma underscores the need for improved understanding of the molecular 
mechanisms that govern tumor cell migration and invasion. 
Gastrin-releasing peptide (GRP) is a gut neuropeptide with mitogenic 
properties that is secreted by neuroblastoma in an autocrine/paracrine fashion [26]. 
We have previously shown that GRP binds to its cell surface receptor, GRPR, to 
stimulate neuroblastoma growth, and that GRPR overexpression increases 
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tumorigenicity and metastatic potential in neuroblastoma cells [43,44]. Further, 
increased expression of GRPR is found in more undifferentiated neuroblastoma that 
are frequently associated with metastatic disease and dismal patient outcomes. 
Conversely, our laboratory has recently shown that targeted silencing of GRPR 
through stable transfection can inhibit tumor growth and metastasis in vivo [110]; 
however, the exact cellular mechanisms responsible for distant organ metastasis in 
neuroblastoma are not clearly defined. 
The capacity for tumor cell migration and invasion through the extracellular 
matrix (ECM) is one of the key components of the metastatic process. A multitude of 
intra- and extra- cellular signaling pathways coordinate to exert molecular changes 
that ultimately allow cancer cells to progress beyond the primary tumor. Integrins are 
a group of heterodimeric transmembrane surface glycoproteins that play a key role 
in the regulation of cell-to-cell and cell-to-ECM attachments, yet also possess the 
capacity to transmit information from the extracellular milieu that can regulate cellular 
growth, survival, and migration [135]. As key mediators of tumor progression, 
integrins allow cells to adapt to changing microenvironments during metastatic 
progression, and it is not surprising that changes in membrane integrin expression 
have been identified in various types of cancer [136]. The association between 
integrin expression and GRP/GRPR signaling in neuroblastoma is heretofore 
undefined. 
 
 
Results 
 
GRP stimulated neuroblastoma cell migration and invasion.  
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To assess the ability of GRP to stimulate cell motility, serum-starved SK-N-
SH cells were cultured with or without GRP. Cell migration and invasion assays were 
independently performed on each cell line using transwell system and relative values 
were calculated, as well as cell count quantification to measure invasion. GRP 
treatment significantly increased SK-N-SH cell migration (Fig. 15A). Furthermore, 
cell counts after GRP-induced invasion were significantly higher when compared to 
controls (Fig. 15B). Given the important role of matrix metalloproteinase (MMP) and 
tissue inhibitor of metalloproteinase (TIMP) in modulating the ECM during cell 
movement, I next wanted to determine whether GRP stimulation leads to altered 
expression of MMP or TIMP [137]. GRP significantly upregulated MMP-2 expression 
in SK-N-SH cells when compared to controls, while the expression of TIMP-1, a 
known inhibitor of MMP-2, was decreased after GRP treatment (Fig. 15C). Taken 
together, these results suggest a critical role for GRP-mediated neuroblastoma cell 
migration and invasion. 
 
GRPR overexpression increased integrin α2, α3, and β1 expression in SK-N-SH.  
GRP overexpression is known to stimulate neuroblastoma cell growth and 
proliferation [108]; however, its relationship to tumor progression and cell motility is 
less defined. In order to better understand the cellular mechanisms underlying 
GRP/GRPR mediated neuroblastoma cell motility, we established stably transfected 
GRPR overexpressing SK-N-SH cells. We then performed gene expression analysis 
using a cDNA GEArray® Microarray kit to identify target genes that may be altered 
as a result of GRPR signaling. We found that GRPR overexpressing SK-N-SH 
human neuroblastoma cells showed increased mRNA levels of integrin α2, α3, and 
β1 (Fig. 16A). Correlative to mRNA, integrin α2, α3, and β1 protein levels were also 
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Figure 15. GRP increases cell migration and invasion by differential expression of 
MMP-2 and TIMP1. (A) GRP treatment (10-7 M) for 24 h increased SK-N-SH cell 
migration in transwell plates. Values are expressed using migrated cell numbers from 
two experiments performed in duplicate. (*= p <0.05 vs. control). (B) GRP also 
stimulated the number of SK-N-SH cells in matrigel-coated transwell plates. Bars 
represent the averages of two experiments performed in duplicate. (*= p <0.05 vs. 
control). (C) Increased MMP-2 but decreased TIMP-1 expressions were observed in SK-
N-SH cells after GRP treatment. 
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Figure 16. GRPR overexpression upregulates integrin α2, α3, and β1 expression in 
SK-N-SH cells and stimulated cell migration. (A) GRPR overexpression resulted in 
increased mRNA levels of integrin α2, α3, and β1 (boxed areas) as measured by 
SuperArray. (B) Western blot analysis was performed with indicated antibodies in GRPR 
overexpressing cells. Total ERK1/2 expression was probed to demonstrate equal protein 
loading. (C) Increased levels of integrin α2, α3, and β1 membrane expression in GRPR 
overexpressing cells as measured by flow cytometry. (D) GRPR overexpressing cells 
with stimulated cell migration rate. Values are expressed using migrated cell numbers 
from two experiments performed in duplicate. (*= p <0.05 vs. control). 
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increased as measured by Western blotting when compared to controls (Fig. 16B). 
In addition, these increased expression of integrin α2, α3, and β1 in GRPR 
overexpressing SK-N-SH cells were further confirmed using flow cytometry (Fig. 
16C). Consistent with GRP-induced cell migration in Figure 1A, stable transfection of 
GRPR overexpressing SK-N-SH cells also resulted in a concomitant increase in cell 
migration (Fig. 16D). Hence, my results support a positive correlation between 
GRPR and integrin expression, indicating that GRPR is important for a cellular 
function of cell migration in neuroblastoma cells by regulating integrin. 
 
Integrin β1 regulates SK-N-SH cell migration.  
Since GRPR overexpression induced SK-N-SH cell migration and increased 
integrin expression, we sought to better characterize this cellular process. First, I 
used small interfering (si) RNA to silence integrin α2, α3, and β1 expression in SK-N-
SH cells, then performed wound healing assays at 24, 48, and 72 h to determine the 
effects on cell migration (Fig. 17A). Wound healing assays have been used to 
measure cell migration, cell proliferation and wound closure. The process of wound 
healing begins by polarizing cells toward the wound, initiating protrusion, migrating 
and closing the wound area. Wound unclosure was measured microscopically and 
relative values were determined. Targeted silencing of integrin β1 (siIntegrin β1) 
significantly decreased cell migration after wounding at 72 h when compared to 
siRNA targeted at integrin α2 and α3 (Fig. 17B). Western blot analysis was used to 
confirm the specificity of siRNA (Fig. 17C).  
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Figure 17. Silencing of integrin α2, α3, and β1 in SK-N-SH cells. (A) SK-N-SH cells 
were transfected with siRNA against integrin α2, α3, and β1. After 48 h, scratches were 
made using 200 µl tips. Wound closure was measured from microscopic images at 24, 
48, and 72 h after wounding (100X magnification). (B) Data are representative of the 
mean distance of unclosure from three independent experiments (*= p <0.05 vs. siNTC). 
(C) Western blot analysis was performed with indicated antibodies in the cells. β-actin 
was used to demonstrate equal protein loading.  
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Integrin β1 is a critical regulator of cell migration in GRPR overexpressing SK-N-SH. 
Given the measurable result of integrin β1 silencing on cell migration in SK-N-
SH cells, I then sought to identify the effect of integrin β1 knockdown in GRPR 
overexpressing SK-N-SH cells. Scratch assays were established with siIntegrin β1 in 
GRPR overexpressing cells and measured at 24, 48, and 72 h for wound unclosure 
as a function of cell migration (Fig. 18A). siRNA inhibition of integrin β1 decreased 
cell migration in GRPR overexpressing SK-N-SH cells after wounding at 72 h 
compared with the non-targeted control GRPR overexpressing cells (Fig. 18B). 
Western blot analysis was used to confirm the specificity of siIntegrin β1 (Fig. 18C). 
In this study, I examined the effects of GRP/GRPR signaling on 
neuroblastoma cell migration and invasion, and determine the role of integrin as it 
relates to GRPR-mediated neuroblastoma cell motility. GRP treatment led to 
increased migration and invasion of neuroblastoma cells. GRPR overexpression not 
only stimulated neuroblastoma cell migration, but also led to the upregulation of 
mRNA, protein, and membrane expression of integrin subunits α2, α3, and β1. 
Moreover, silencing of integrin β1 led to significant inhibition of cell migration 
suggesting its role as a potential key regulator of GRPR-mediated neuroblastoma 
cell migration and invasion. 
 
 
Discussion 
As a neuroendocrine tumor, neuroblastoma can exhibit mitogenic behavior in 
response to autocrine and paracrine stimulation, particularly in response to GRP. In 
fact, GRP/GRPR signaling has been shown to significantly induce neuroblastoma  
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Figure 18. Silencing of integrin β1 decreases cell migration in GRPR 
overexpressing SK-N-SH cells. (A) GRPR overexpressing SK-N-SH cells were 
transfected with siRNA against integrin β1. After 48 h, scratches were made using 200 µl 
tips. Wound closure was measured from microscopic images at 24, 48, and 72 h after 
wounding (100X magnification) (B) Data are representative of the mean distance of 
unclosure from three independent experiments (*= p <0.05 vs. siNTC). (C) Western blot 
analysis was performed with indicated antibodies in the cells. β-actin was used to 
demonstrate equal protein loading.  
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cell growth through the PI3K/Akt pathway [107]. Advances in the treatment of high-
risk neuroblastoma have focused on abrogating the progression of metastatic and 
recurrent disease, but with less than satisfactory results. Hence, a better knowledge 
of the molecular mechanisms involved in GRPR-mediated neuroblastoma cell 
motility may provide potential novel therapeutic targets. In this study I demonstrate 
that signaling through the GRP/GRPR axis results in neuroblastoma cell migration 
and invasion in vitro, and that GRPR signaling mediates its effects on neuroblastoma 
cell motility through upregulation of α2, α3, and β1 integrin subunits. Furthermore, I 
have shown that integrin β1 expression is particularly critical to GRPR-mediated cell 
migration as evidenced by the significant decrease observed in neuroblastoma cell 
migration upon inhibition of integrin β1 with siRNA. 
It was demonstrated that GRP can stimulate cell migration in prostate [138] 
and breast cancers [139] through binding to its cognate receptor, GRPR. Similar 
studies using the GRP analog, BBS, have shown that BBS/GRPR signaling 
enhances the migratory and invasive capacity of colorectal carcinoma cells in a 
dose-dependent fashion [140], albeit the exact molecular mechanisms still remain 
unclear. While the role of GRPR signaling in neuroblastoma tumorigenesis has been 
established [110], the effects of such signaling events as they relate to 
neuroblastoma cell migration and invasion have not been examined. In the present 
study, our findings show that both GRP treatment and GRPR overexpression lead to 
increased motility of SK-N-SH neuroblastoma cells. The ability of a cancer cell to 
penetrate the ECM is paramount for tumor progression. Neoplastic cells take 
advantage of enzymatic digestion of the ECM by MMPs to accomplish these tasks. 
Interestingly, treatment of SK-N-SH cells with GRP led to increased expression of 
MMP-2 while expression of the MMP-inhibiting enzyme TIMP-1 was downregulated, 
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suggesting that GRP may play a secondary role in modulating the extracellular 
environment to allow for tumor cell motility through the ECM. In fact, it is known that 
MMPs play a crucial role in tumor progression through regulation of the tumor 
microenvironment [141], and that dysregulation of the balance between MMP 
proteolysis and TIMP expression is linked to cancer cell invasion [142]. Further 
studies examining the relationship between GRP signaling and regulation of the 
MMP/TIMP balance in neuroblastoma tumor progression will be needed. 
Since cell migration and invasion, as well as intravasation and extravasation, 
are fundamental requirements of cancer cells during metastasis, we sought to further 
characterize changes in gene expression that may reflect cellular changes in tumor 
progression. As such, gene expression profiles between GRPR overexpressing cells 
and control cells were created using cDNA microarray analysis in order to identify 
gene targets. Comparative gene expression analysis showed that GRPR 
overexpression led to the upregulation of integrin α2, α3, and β1 mRNA. These 
findings were further corroborated with Western blot and flow cytometric analysis. 
Collectively, these findings show that GRPR overexpression increases the 
expression of integrin α2, α3, and β1 in SK-N-SH cells, and outlines a potential 
relationship between GRP/GRPR-induced cell migration/invasion and integrin 
expression, and emphasize the role of neuroendocrine signaling in neuroblastoma 
tumor progression, which underscore the notion that cell-ECM interactions can 
regulate molecular signaling in response to mitogenic factors.  
As the prominent receptor for the ECM, integrins function beyond simple cell 
adhesion and can influence numerous cellular functions in response to signals from 
the environment. Previous studies have suggested that changes in integrin 
expression by tumor cells can modulate growth and survival, as well as cell adhesion 
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and migration [143]. Of interest in the present study is the relationship of GRP/GRPR 
induced integrin expression to cell migration and invasion. I first wanted to test which 
integrin subunit plays a role in regulating cell migration in SK-N-SH cells. I performed 
the knockdown of integrin α2, α3, and β1 subunits using siRNA against each integrin 
subunit and cell migration assay in SK-N-SH cells. In fact, the decrease in cell 
movement seen on scratch assay was significantly greater after integrin β1 silencing 
when compared to integrin α2 and α3 silencing. These effects were not rescued with 
GRPR overexpression, suggesting the crucial role of integrin β1 in GRPR-mediated 
cell motility. The dysregulation of cell adhesion molecules, particularly integrins, is 
well established in human cancers, and overexpression of the integrin β1 subunit is 
associated with increased metastatic potential in breast [144] and lung cancers [145]. 
Although previous reports have suggested that decreased integrin β1 expression in 
neuroblastoma cell lines leads to increased cell migration in vivo [146], our studies 
do not corroborate this finding. 
In conclusion, the present study demonstrates that GRP and its associated 
receptor, GRPR, provide a significant molecular access point for the induction and 
stimulation of neuroblastoma tumor cell motility through cellular mechanisms that 
likely involve the modulation of integrin subunit expression, particularly integrin β1. 
The role of β1 integrin expression in cell attachment and invasion has been 
implicated in other cancers [147]. Further studies will be needed to identify the 
molecular mechanisms underlying GRP-mediated integrin expression and how these 
interactions contribute to the metastatic potential of neuroblastoma.  
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CHAPTER V 
 
 
SUMMARY AND FUTURE DIRECTIONS 
 
 
SUMMARY 
The significant findings from these studies are described here. The findings 
that lead to the conclusion that FAK mediates GRP/GRPR-induced neuroblastoma 
progression are: 1) FAK expression correlates with GRPR expression, which 
corresponds to tumor malignancy; higher expression in more aggressive type of 
tumor; 2) GRPR overexpression increased FAK expression and cell migration 
whereas GRPR silencing decreased FAK and MYCN expression, cell viability and 
colony formation; 3) FAK expression is important for the regulation of neuroblastoma 
proliferative capabilities, cell size and anchorage-independent growth, which are a 
key features of tumor malignant potential; 4) BBS treatment significantly enhances 
the metastasis potential in human neuroblastoma xenografts in nude mice and 
effects can be reversed with a FAK inhibitor. Furthermore, the findings that lead to 
the conclusion that integrin β1 plays a role in GRP/GRPR-induced cell migration are: 
1) GRP increased neuroblastoma cell migration and invasion in MYCN single copy, 
SK-N-SH cells, which do not increase FAK activity by GRP treatment. 2) GRPR 
overexpression stimulated cell migration and upregulated integrin α2, α3, and β1 
protein as well as mRNA expression. 3) Targeted silencing of integrin β1 in GRPR 
overexpressing SK-N-SH cells inhibited cell migration. Altogether, these findings 
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indicate that FAK and integrin play a functionally important role in mediating the 
stimulatory effects of GRP/GRPR during the progression of neuroblastoma 
pathogenesis.  
 
 
FUTURE DIRECTIONS 
Invasion and metastasis are critical hallmarks in cancer [148]. Metastatic 
lesions, which are often implicated in resistance to adjuvant therapy, remain as one 
of the major causes for high mortality from cancer [149]. In neuroblastoma, >50% of 
patients have metastatic disease at the time of diagnosis, thus creating major 
challenges for treatment. Moreover, ‘high-risk’ group of neuroblastomas often 
relapse despite initial response to therapies. Frequently, tumors acquire drug 
resistance or aggressive phenotypes through the selection of rare resistant clones 
from heterogeneous tumor environment, which can result in major clinical obstacles 
in the treatment of neuroblastoma [150]. Thus, a better understanding of the 
mechanisms and signaling pathways that contribute to metastasis will be valuable in 
the development of novel therapies.  
 
Mechanism of FAK-mediated inhibition of cell growth  
My studies have shown that FAK expression is crucial for various factors 
regulating tumorigenesis in neuroblastoma. In particular, FAK silencing significantly 
inhibited cell growth and anchorage-independent growth in vitro and in vivo. 
Proposed in vitro experiments would evaluate the effects of FAK silencing on the cell 
cycle (flow cytometry, BrdU incorporation, protein expression of cell cycle regulators 
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such as Cyclin D, Cyclin B1, and Histone H3 phosphorylation) and apoptosis 
(TUNEL assay, Cell Death ELISA, protein expression of apoptotic markers such as 
Bcl-2 family proteins, Caspase 3 and cleaved PARP). These studies are important 
because an effective agent is critical to diminish the harmful side effects seen with 
current neuroblastoma treatments. These also would be helpful to develop the 
potential synergistic benefits of multi-targeted therapy. 
 
Mechanism of upregulated expression of focal adhesion proteins in GRPR 
overexpressing cells  
My studies have shown that focal adhesion proteins including FAK and 
integrin are highly expressed in GRPR overexpressing SK-N-SH cells. In particular, 
the mRNA level of FAK did not increase but the protein level increased, indicating 
the modulation of FAK protein in GRPR overexpression is a post-transcriptional 
regulation process. According to immunofluorescence staining data, the protein 
expression of GRPR and FAK at the focal adhesions is prominent. Enhanced 
expression of integrin may show in a similar manner in GRPR overexpressing cells. 
If so, proposed in vitro experiments would evaluate the effects of GRPR 
overexpression on the protein stability of focal adhesion proteins (membrane protein 
extraction, Cycloheximide/MG132 treatment, protein half-life, protein degradation 
assay). These studies would provide evidence of how GRPR plays a role to interact 
with other membrane proteins and could further emphasize the importance of 
targeting GRPR in GRPR overexpressing cancer cells.  
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Mechanism of GRP/GRPR regulation of MYCN 
The most widely associated feature with neuroblastoma prognosis is the level 
of MYCN amplification. Occurring in up to 25% of primary tumors, MYCN is strongly 
correlated with advanced-stage disease and treatment failure [14,15]. MYCN is an 
oncogenic transcription factor which functions in the regulation of proliferation, 
differentiation, transformation and apoptosis [151,152]. MYCN has been found to 
directly regulate the transcriptional expression of mouse double minute 2 homolog 
(MDM2), the inhibitor of p53 and FAK, and cellular retinoic acid-binding protein II 
(CRABP-II), which appears to be related cell motility [153]. However, because it is a 
nuclear transcription factor, it is difficult to directly target MYCN with small-molecule 
inhibitors.  
Our laboratory and others have found that siRNA targeted to MYCN resulted 
in increased differentiation and apoptosis, with concurrent growth inhibition 
[154,155]. Other mechanisms of inhibiting MYCN are aimed at crucial upstream 
regulators of the oncogene, such as the PI3K/AKT survival pathway. It has been 
demonstrated that inhibition of PI3K/AKT pathway components resulted in MYCN 
destabilization via a GSK3β-regulated mechanism [20]. It is unknown exactly how 
GRPR targeting can regulate MYCN in neuroblastoma, therefore it will be interesting 
to investigate whether GRPR expression correlates with MYCN activity. In particular, 
since MYCN regulates the expression of FAK by binding to a FAK promoter region in 
neuroblastoma, it will be intriguing if there is a potential axis of GRPR/MYCN/FAK. In 
order to study this, I propose an experimental design in which MYCN-luciferase 
promoter constructs are transfected in neuroblastoma cells with high versus low 
levels of GRPR. Moreover, the stability and degradation of MYCN expression could 
be examined using Cycloheximide/MG132 treatment and ubiquitination assay. I also 
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propose that these future experiments should utilize inducible expression systems. 
This will help determine whether GRPR expression plays a role in mediating the 
activity of MYCN, and will further determine how it affects the regulation of FAK 
expression. In regards to future therapies, an affiliation of this magnitude would not 
only define GRP/GRPR as a specific neuroblastoma prognostic marker but would 
potentially provide the mechanism and an effective target for this important subset of 
advanced, MYCN-amplified neuroblastoma. 
 
Identification of the mediators between GRPR and FAK  
My studies have shown the correlation between GRPR and FAK in 
neuroblastoma. In particular, I have provided data for the molecular, functional and 
physiological roles of FAK in GRPR-mediated neuroblastoma growth and metastasis 
in vitro and in vivo. However, still I have not answered how GRP/GRPR signaling 
actually interacts with FAK. Long et al. have demonstrated that SRC3Δ4 is an 
important mediator between EGF receptor (EGFR) and FAK to promote cell 
migration [156]. Furthermore, they found that overexpression of SRC3Δ4 promoted 
breast tumor metastasis, coordinating the signaling between EGFR and FAK while 
knockdown of SRC3Δ4 expression significantly decreases EGF-induced FAK 
activation and cell migration. They identified SRC3Δ4 as the missing adaptor protein 
that bridges the interaction between EGFR and FAK upon EGF stimulation. This 
finding suggests that SRC3Δ4 represents another potential therapeutic target for 
counter acting cancer metastasis. Src is a highly possible candidate for mediating 
signaling between GRPR and FAK because GRP can induce Src activity, which can 
act as an initiator of FAK activation. Identifying of the mediator and its roles would be 
able to provide another new therapeutic target for better neuroblastoma treatments. 
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Combined targeting of GRPR and FAK in neuroblastoma 
My studies have shown the role of FAK in GRPR-mediated neuroblastoma 
progression. In particular, I have shown the FAK overexpression can rescue 
malignant potentials in GRPR silencing cells while FAK inhibition blocks GRP-
induced cell growth and metastasis. I have not demonstrated the combined effects of 
targeting both GRPR and FAK because silencing of either of each already showed a 
great impact on inhibition of tumor growth in vivo. However, it might be difficult to 
show the similar effects in the actual neuroblastoma patients, especially in patients 
who harbor more aggressive type of neuroblastoma, receiving a combination 
therapy. Moreover, even though I suggested that FAK is a critical downstream target 
of GRP/GRPR signaling pathway, since both GRPR and FAK are such an upstream-
acting, intermediate protein in cells, many signals are overlapped by them but not all.  
By testing the combination cytotoxic effects of targeting GRPR and FAK together, we 
may expect a better therapeutic strategy in neuroblastoma treatments, overcoming 
drug resistance in heterogeneous tumors, and by taking advantage of tumor growth 
kinetics with increasing the dose-density of combination treatments. The overall goal 
is to improve clinical efficacy with acceptable toxicity. 
 
  
 72 
REFERENCES 
 
1. Herrera JM, Krebs A, Harris P, Barriga F (2000) Childhood tumors. Surg Clin North 
Am 80: 747-760, xii. 
2. Schwab M, Westermann F, Hero B, Berthold F (2003) Neuroblastoma: biology and 
molecular and chromosomal pathology. The lancet oncology 4: 472-480. 
3. Berthold F, Hero B (2000) Neuroblastoma: current drug therapy recommendations as 
part of the total treatment approach. Drugs 59: 1261-1277. 
4. Novakovic B (1994) U.S. childhood cancer survival, 1973-1987. Medical and pediatric 
oncology 23: 480-486. 
5. Smith EI, Castleberry RP (1990) Neuroblastoma. Curr Probl Surg 27: 573-620. 
6. Grosfeld JL (1999) Risk-based management: current concepts of treating malignant 
solid tumors of childhood. J Am Coll Surg 189: 407-425. 
7. Cotterill SJ, Pearson AD, Pritchard J, Foot AB, Roald B, et al. (2000) Clinical 
prognostic factors in 1277 patients with neuroblastoma: results of The European 
Neuroblastoma Study Group 'Survey' 1982-1992. Eur J Cancer 36: 901-908. 
8. Joshi VV, Cantor AB, Brodeur GM, Look AT, Shuster JJ, et al. (1993) Correlation 
between morphologic and other prognostic markers of neuroblastoma. A study of 
histologic grade, DNA index, N-myc gene copy number, and lactic 
dehydrogenase in patients in the Pediatric Oncology Group. Cancer 71: 3173-
3181. 
9. Nakagawara A, Arima-Nakagawara M, Scavarda NJ, Azar CG, Cantor AB, et al. 
(1993) Association between high levels of expression of the TRK gene and 
favorable outcome in human neuroblastoma. The New England journal of 
medicine 328: 847-854. 
10. Kogner P, Barbany G, Dominici C, Castello MA, Raschella G, et al. (1993) 
Coexpression of messenger RNA for TRK protooncogene and low affinity nerve 
growth factor receptor in neuroblastoma with favorable prognosis. Cancer 
research 53: 2044-2050. 
11. Nakagawara A, Arima M, Azar CG, Scavarda NJ, Brodeur GM (1992) Inverse 
relationship between trk expression and N-myc amplification in human 
neuroblastomas. Cancer research 52: 1364-1368. 
 73 
12. Hicks MJ, Mackay B (1995) Comparison of ultrastructural features among 
neuroblastic tumors: maturation from neuroblastoma to ganglioneuroma. 
Ultrastructural pathology 19: 311-322. 
13. Peuchmaur M, d'Amore ES, Joshi VV, Hata J, Roald B, et al. (2003) Revision of the 
International Neuroblastoma Pathology Classification: confirmation of favorable 
and unfavorable prognostic subsets in ganglioneuroblastoma, nodular. Cancer 
98: 2274-2281. 
14. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM (1984) Amplification of 
N-myc in untreated human neuroblastomas correlates with advanced disease 
stage. Science 224: 1121-1124. 
15. Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, et al. (1985) Association of 
multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. 
The New England journal of medicine 313: 1111-1116. 
16. Ribatti D, Raffaghello L, Pastorino F, Nico B, Brignole C, et al. (2002) In vivo 
angiogenic activity of neuroblastoma correlates with MYCN oncogene 
overexpression. International journal of cancer Journal international du cancer 
102: 351-354. 
17. Bowen KA, Chung DH (2009) Recent advances in neuroblastoma. Current opinion in 
pediatrics 21: 350-356. 
18. Norris MD, Bordow SB, Marshall GM, Haber PS, Cohn SL, et al. (1996) Expression 
of the gene for multidrug-resistance-associated protein and outcome in patients 
with neuroblastoma. The New England journal of medicine 334: 231-238. 
19. Bordow SB, Haber M, Madafiglio J, Cheung B, Marshall GM, et al. (1994) 
Expression of the multidrug resistance-associated protein (MRP) gene correlates 
with amplification and overexpression of the N-myc oncogene in childhood 
neuroblastoma. Cancer research 54: 5036-5040. 
20. Chesler L, Schlieve C, Goldenberg DD, Kenney A, Kim G, et al. (2006) Inhibition of 
phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant 
progression in neuroblastoma. Cancer research 66: 8139-8146. 
21. Kang J, Rychahou PG, Ishola TA, Mourot JM, Evers BM, et al. (2008) N-myc is a 
novel regulator of PI3K-mediated VEGF expression in neuroblastoma. Oncogene 
27: 3999-4007. 
 74 
22. Langer I, Vertongen P, Perret J, Fontaine J, Atassi G, et al. (2000) Expression of 
vascular endothelial growth factor (VEGF) and VEGF receptors in human 
neuroblastomas. Medical and pediatric oncology 34: 386-393. 
23. Fukuzawa M, Sugiura H, Koshinaga T, Ikeda T, Hagiwara N, et al. (2002) 
Expression of vascular endothelial growth factor and its receptor Flk-1 in human 
neuroblastoma using in situ hybridization. Journal of pediatric surgery 37: 1747-
1750. 
24. Beierle EA, Massoll NA, Hartwich J, Kurenova EV, Golubovskaya VM, et al. (2008) 
Focal adhesion kinase expression in human neuroblastoma: 
immunohistochemical and real-time PCR analyses. Clinical cancer research : an 
official journal of the American Association for Cancer Research 14: 3299-3305. 
25. Beierle EA, Trujillo A, Nagaram A, Kurenova EV, Finch R, et al. (2007) N-MYC 
regulates focal adhesion kinase expression in human neuroblastoma. The 
Journal of biological chemistry 282: 12503-12516. 
26. Gustafson WC, De Berry BB, Evers BM, Chung DH (2005) Role of gastrointestinal 
hormones in neuroblastoma. World J Surg 29: 281-286. 
27. Black CT, Atkinson JB (1997) Neuroblastoma. Semin Pediatr Surg 6: 2-10. 
28. Maris JM, Matthay KK (1999) Molecular biology of neuroblastoma. J Clin Oncol 17: 
2264-2279. 
29. Greeley GH, Jr., Partin M, Spannagel A, Dinh T, Hill FL, et al. (1986) Distribution of 
bombesin-like peptides in the alimentary canal of several vertebrate species. 
Regul Pept 16: 169-181. 
30. Rozengurt E, Sinnett-Smith J (1983) Bombesin stimulation of DNA synthesis and cell 
division in cultures of Swiss 3T3 cells. Proc Natl Acad Sci U S A 80: 2936-2940. 
31. Fender HR, Curtis DJ, Rayford PL, Thompson JC (1976) Effect of bombesin on 
serum gastrin and cholecystokinin in dogs. Surg Forum 27: 414-416. 
32. Ghatei MA, Jung RT, Stevenson JC, Hillyard CJ, Adrian TE, et al. (1982) Bombesin: 
action on gut hormones and calcium in man. J Clin Endocrinol Metab 54: 980-
985. 
33. Alexander RW, Upp JR, Jr., Poston GJ, Gupta V, Townsend CM, Jr., et al. (1988) 
Effects of bombesin on growth of human small cell lung carcinoma in vivo. 
Cancer Res 48: 1439-1441. 
34. Rozengurt E (1988) Bombesin-induction of cell proliferation in 3T3 cells. Specific 
receptors and early signaling events. Ann N Y Acad Sci 547: 277-292. 
 75 
35. Nagakawa O, Ogasawara M, Fujii H, Murakami K, Murata J, et al. (1998) Effect of 
prostatic neuropeptides on invasion and migration of PC-3 prostate cancer cells. 
Cancer Lett 133: 27-33. 
36. Bold RJ, Ishizuka J, Yao CZ, Townsend CM, Jr., Thompson JC (1998) Bombesin 
stimulates in vitro growth of human breast cancer independent of estrogen 
receptors status. Anticancer Res 18: 4051-4056. 
37. Corjay MH, Dobrzanski DJ, Way JM, Viallet J, Shapira H, et al. (1991) Two distinct 
bombesin receptor subtypes are expressed and functional in human lung 
carcinoma cells. J Biol Chem 266: 18771-18779. 
38. Hajri A, Koenig M, Balboni G, Damge C (1996) Expression and characterization of 
gastrin-releasing peptide receptor in normal and cancerous pancreas. Pancreas 
12: 25-35. 
39. Sun B, Halmos G, Schally AV, Wang X, Martinez M (2000) Presence of receptors for 
bombesin/gastrin-releasing peptide and mRNA for three receptor subtypes in 
human prostate cancers. Prostate 42: 295-303. 
40. Carroll RE, Ostrovskiy D, Lee S, Danilkovich A, Benya RV (2000) Characterization of 
gastrin-releasing peptide and its receptor aberrantly expressed by human colon 
cancer cell lines. Mol Pharmacol 58: 601-607. 
41. Kogner P (1995) Neuropeptides in neuroblastomas and ganglioneuromas. Progress 
in brain research 104: 325-338. 
42. Maris JM, Matthay KK (1999) Molecular biology of neuroblastoma. Journal of clinical 
oncology : official journal of the American Society of Clinical Oncology 17: 2264-
2279. 
43. Kim S, Hu W, Kelly DR, Hellmich MR, Evers BM, et al. (2002) Gastrin-releasing 
peptide is a growth factor for human neuroblastomas. Ann Surg 235: 621-629; 
discussion 629-630. 
44. Qiao J, Kang J, Cree J, Evers BM, Chung DH (2005) Gastrin-releasing peptide-
induced down-regulation of tumor suppressor protein PTEN (phosphatase and 
tensin homolog deleted on chromosome ten) in neuroblastomas. Ann Surg 241: 
684-691; discussion 691-682. 
45. Sotomayor S, Munoz-Moreno L, Carmena MJ, Schally AV, Sanchez-Chapado M, et 
al. (2010) Regulation of HER expression and transactivation in human prostate 
cancer cells by a targeted cytotoxic bombesin analog (AN-215) and a bombesin 
 76 
antagonist (RC-3095). International journal of cancer Journal international du 
cancer 127: 1813-1822. 
46. Cornelio DB, Roesler R, Schwartsmann G (2007) Gastrin-releasing peptide receptor 
as a molecular target in experimental anticancer therapy. Annals of oncology : 
official journal of the European Society for Medical Oncology / ESMO 18: 1457-
1466. 
47. Kozacko MF, Mang TS, Schally AV, Priore RL, Liebow C (1996) Bombesin 
antagonist prevents CO2 laser-induced promotion of oral cancer. Proceedings of 
the National Academy of Sciences of the United States of America 93: 2953-
2957. 
48. Szepeshazi K, Schally AV, Halmos G, Lamharzi N, Groot K, et al. (1997) A single in 
vivo administration of bombesin antagonist RC-3095 reduces the levels and 
mRNA expression of epidermal growth factor receptors in MXT mouse mammary 
cancers. Proceedings of the National Academy of Sciences of the United States 
of America 94: 10913-10918. 
49. Koppan M, Halmos G, Arencibia JM, Lamharzi N, Schally AV (1998) 
Bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II inhibit 
tumor growth and decrease the levels and mRNA expression of epidermal 
growth factor receptors in H-69 small cell lung carcinoma. Cancer 83: 1335-1343. 
50. Kiaris H, Schally AV, Sun B, Armatis P, Groot K (1999) Inhibition of growth of human 
malignant glioblastoma in nude mice by antagonists of bombesin/gastrin-
releasing peptide. Oncogene 18: 7168-7173. 
51. Szepeshazi K, Halmos G, Schally AV, Arencibia JM, Groot K, et al. (1999) Growth 
inhibition of experimental pancreatic cancers and sustained reduction in 
epidermal growth factor receptors during therapy with hormonal peptide analogs. 
Journal of cancer research and clinical oncology 125: 444-452. 
52. Jungwirth A, Galvan G, Pinski J, Halmos G, Szepeshazi K, et al. (1997) Luteinizing 
hormone-releasing hormone antagonist Cetrorelix (SB-75) and bombesin 
antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate 
cancer in nude mice. The Prostate 32: 164-172. 
53. Chatzistamou I, Schally AV, Sun B, Armatis P, Szepeshazi K (2000) Inhibition of 
growth of OV-1063 human epithelial ovarian cancers and c- jun and c- fos 
oncogene expression by bombesin antagonists. British journal of cancer 83: 906-
913. 
 77 
54. Dantas Ados S, Luft T, Henriques JA, Schwartsmann G, Roesler R (2006) Opposite 
effects of low and high doses of the gastrin-releasing peptide receptor antagonist 
RC-3095 on memory consolidation in the hippocampus: possible involvement of 
the GABAergic system. Peptides 27: 2307-2312. 
55. Schwartsmann G, DiLeone LP, Horowitz M, Schunemann D, Cancella A, et al. (2006) 
A phase I trial of the bombesin/gastrin-releasing peptide (BN/GRP) antagonist 
RC3095 in patients with advanced solid malignancies. Investigational new drugs 
24: 403-412. 
56. Luo M, Fan H, Nagy T, Wei H, Wang C, et al. (2009) Mammary epithelial-specific 
ablation of the focal adhesion kinase suppresses mammary tumorigenesis by 
affecting mammary cancer stem/progenitor cells. Cancer research 69: 466-474. 
57. Liu W, Bloom DA, Cance WG, Kurenova EV, Golubovskaya VM, et al. (2008) FAK 
and IGF-IR interact to provide survival signals in human pancreatic 
adenocarcinoma cells. Carcinogenesis 29: 1096-1107. 
58. Golubovskaya VM, Gross S, Kaur AS, Wilson RI, Xu LH, et al. (2003) Simultaneous 
inhibition of focal adhesion kinase and SRC enhances detachment and apoptosis 
in colon cancer cell lines. Molecular cancer research : MCR 1: 755-764. 
59. Owens LV, Xu L, Craven RJ, Dent GA, Weiner TM, et al. (1995) Overexpression of 
the focal adhesion kinase (p125FAK) in invasive human tumors. Cancer Res 55: 
2752-2755. 
60. Judson PL, He X, Cance WG, Van Le L (1999) Overexpression of focal adhesion 
kinase, a protein tyrosine kinase, in ovarian carcinoma. Cancer 86: 1551-1556. 
61. Cance WG, Harris JE, Iacocca MV, Roche E, Yang X, et al. (2000) 
Immunohistochemical analyses of focal adhesion kinase expression in benign 
and malignant human breast and colon tissues: correlation with preinvasive and 
invasive phenotypes. Clinical cancer research : an official journal of the American 
Association for Cancer Research 6: 2417-2423. 
62. Weiner TM, Liu ET, Craven RJ, Cance WG (1993) Expression of focal adhesion 
kinase gene and invasive cancer. Lancet 342: 1024-1025. 
63. Turner CE (2000) Paxillin and focal adhesion signalling. Nature cell biology 2: E231-
236. 
64. Schaller MD (2001) Biochemical signals and biological responses elicited by the 
focal adhesion kinase. Biochimica et biophysica acta 1540: 1-21. 
 78 
65. Beierle EA, Ma X, Trujillo A, Kurenova EV, Cance WG, et al. (2010) Inhibition of 
focal adhesion kinase and src increases detachment and apoptosis in human 
neuroblastoma cell lines. Molecular carcinogenesis 49: 224-234. 
66. Megison ML, Stewart JE, Nabers HC, Gillory LA, Beierle EA (2012) FAK inhibition 
decreases cell invasion, migration and metastasis in MYCN amplified 
neuroblastoma. Clin Exp Metastasis. 
67. Beierle EA, Ma X, Stewart J, Nyberg C, Trujillo A, et al. (2010) Inhibition of focal 
adhesion kinase decreases tumor growth in human neuroblastoma. Cell cycle 9: 
1005-1015. 
68. Golubovskaya VM, Nyberg C, Zheng M, Kweh F, Magis A, et al. (2008) A small 
molecule inhibitor, 1,2,4,5-benzenetetraamine tetrahydrochloride, targeting the 
y397 site of focal adhesion kinase decreases tumor growth. Journal of medicinal 
chemistry 51: 7405-7416. 
69. Roberts WG, Ung E, Whalen P, Cooper B, Hulford C, et al. (2008) Antitumor activity 
and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271. 
Cancer research 68: 1935-1944. 
70. Bagi CM, Roberts GW, Andresen CJ (2008) Dual focal adhesion kinase/Pyk2 
inhibitor has positive effects on bone tumors: implications for bone metastases. 
Cancer 112: 2313-2321. 
71. Siu LL, Pili R, Duran I, Messersmith WA, Chen EX, et al. (2008) Phase I study of 
MGCD0103 given as a three-times-per-week oral dose in patients with advanced 
solid tumors. Journal of clinical oncology : official journal of the American Society 
of Clinical Oncology 26: 1940-1947. 
72. Hynes RO (2002) Integrins: bidirectional, allosteric signaling machines. Cell 110: 
673-687. 
73. Previtali SC, Feltri ML, Archelos JJ, Quattrini A, Wrabetz L, et al. (2001) Role of 
integrins in the peripheral nervous system. Progress in neurobiology 64: 35-49. 
74. Iozzo RV (1998) Matrix proteoglycans: from molecular design to cellular function. 
Annual review of biochemistry 67: 609-652. 
75. Humphries JD, Byron A, Humphries MJ (2006) Integrin ligands at a glance. Journal 
of cell science 119: 3901-3903. 
76. Brakebusch C, Bouvard D, Stanchi F, Sakai T, Fassler R (2002) Integrins in invasive 
growth. The Journal of clinical investigation 109: 999-1006. 
 79 
77. Desgrosellier JS, Cheresh DA (2010) Integrins in cancer: biological implications and 
therapeutic opportunities. Nature reviews Cancer 10: 9-22. 
78. Burridge K, Turner CE, Romer LH (1992) Tyrosine phosphorylation of paxillin and 
pp125FAK accompanies cell adhesion to extracellular matrix: a role in 
cytoskeletal assembly. The Journal of cell biology 119: 893-903. 
79. Lukashev ME, Sheppard D, Pytela R (1994) Disruption of integrin function and 
induction of tyrosine phosphorylation by the autonomously expressed beta 1 
integrin cytoplasmic domain. The Journal of biological chemistry 269: 18311-
18314. 
80. Schaller MD, Parsons JT (1995) pp125FAK-dependent tyrosine phosphorylation of 
paxillin creates a high-affinity binding site for Crk. Molecular and cellular biology 
15: 2635-2645. 
81. Guan JL (2010) Integrin signaling through FAK in the regulation of mammary stem 
cells and breast cancer. IUBMB life 62: 268-276. 
82. Shibue T, Weinberg RA (2009) Integrin beta1-focal adhesion kinase signaling directs 
the proliferation of metastatic cancer cells disseminated in the lungs. 
Proceedings of the National Academy of Sciences of the United States of 
America 106: 10290-10295. 
83. Favrot MC, Combaret V, Goillot E, Lutz P, Frappaz D, et al. (1991) Expression of 
integrin receptors on 45 clinical neuroblastoma specimens. International journal 
of cancer Journal international du cancer 49: 347-355. 
84. Judware R, Culp LA (1995) Over-expression of transfected N-myc oncogene in 
human SKNSH neuroblastoma cells down-regulates expression of beta 1 integrin 
subunit. Oncogene 11: 2599-2607. 
85. Tanaka N, Fukuzawa M (2008) MYCN downregulates integrin alpha1 to promote 
invasion of human neuroblastoma cells. International journal of oncology 33: 815-
821. 
86. Millard M, Odde S, Neamati N (2011) Integrin targeted therapeutics. Theranostics 1: 
154-188. 
87. Parsons JT (2003) Focal adhesion kinase: the first ten years. J Cell Sci 116: 1409-
1416. 
88. Sinnett-Smith J, Zachary I, Valverde AM, Rozengurt E (1993) Bombesin stimulation 
of p125 focal adhesion kinase tyrosine phosphorylation. Role of protein kinase C, 
 80 
Ca2+ mobilization, and the actin cytoskeleton. The Journal of biological 
chemistry 268: 14261-14268. 
89. Daniel TO, Abrahamson D (2000) Endothelial signal integration in vascular assembly. 
Annual review of physiology 62: 649-671. 
90. Eliceiri BP, Cheresh DA (2001) Adhesion events in angiogenesis. Current opinion in 
cell biology 13: 563-568. 
91. Eliceiri BP (2001) Integrin and growth factor receptor crosstalk. Circulation research 
89: 1104-1110. 
92. Orr AW, Murphy-Ullrich JE (2004) Regulation of endothelial cell function BY FAK and 
PYK2. Frontiers in bioscience : a journal and virtual library 9: 1254-1266. 
93. Hildebrand JD, Schaller MD, Parsons JT (1993) Identification of sequences required 
for the efficient localization of the focal adhesion kinase, pp125FAK, to cellular 
focal adhesions. The Journal of cell biology 123: 993-1005. 
94. Tachibana K, Sato T, D'Avirro N, Morimoto C (1995) Direct association of pp125FAK 
with paxillin, the focal adhesion-targeting mechanism of pp125FAK. The Journal 
of experimental medicine 182: 1089-1099. 
95. Liu S, Thomas SM, Woodside DG, Rose DM, Kiosses WB, et al. (1999) Binding of 
paxillin to alpha4 integrins modifies integrin-dependent biological responses. 
Nature 402: 676-681. 
96. Chen HC, Appeddu PA, Parsons JT, Hildebrand JD, Schaller MD, et al. (1995) 
Interaction of focal adhesion kinase with cytoskeletal protein talin. The Journal of 
biological chemistry 270: 16995-16999. 
97. Miyamoto S, Teramoto H, Gutkind JS, Yamada KM (1996) Integrins can collaborate 
with growth factors for phosphorylation of receptor tyrosine kinases and MAP 
kinase activation: roles of integrin aggregation and occupancy of receptors. J Cell 
Biol 135: 1633-1642. 
98. Giancotti FG, Ruoslahti E (1999) Integrin signaling. Science 285: 1028-1032. 
99. Schwartz MA, Baron V (1999) Interactions between mitogenic stimuli, or, a thousand 
and one connections. Curr Opin Cell Biol 11: 197-202. 
100. Schneller M, Vuori K, Ruoslahti E (1997) Alphavbeta3 integrin associates with 
activated insulin and PDGFbeta receptors and potentiates the biological activity 
of PDGF. EMBO J 16: 5600-5607. 
 81 
101. Sieg DJ, Hauck CR, Ilic D, Klingbeil CK, Schaefer E, et al. (2000) FAK integrates 
growth-factor and integrin signals to promote cell migration. Nat Cell Biol 2: 249-
256. 
102. Glover S, Delaney M, Dematte C, Kornberg L, Frasco M, et al. (2004) 
Phosphorylation of focal adhesion kinase tyrosine 397 critically mediates gastrin-
releasing peptide's morphogenic properties. J Cell Physiol 199: 77-88. 
103. Aprikian AG, Tremblay L, Han K, Chevalier S (1997) Bombesin stimulates the 
motility of human prostate-carcinoma cells through tyrosine phosphorylation of 
focal adhesion kinase and of integrin-associated proteins. Int J Cancer 72: 498-
504. 
104. Markwalder R, Reubi JC (1999) Gastrin-releasing peptide receptors in the human 
prostate: relation to neoplastic transformation. Cancer Res 59: 1152-1159. 
105. Slack JK, Adams RB, Rovin JD, Bissonette EA, Stoker CE, et al. (2001) Alterations 
in the focal adhesion kinase/Src signal transduction pathway correlate with 
increased migratory capacity of prostate carcinoma cells. Oncogene 20: 1152-
1163. 
106. Zheng DQ, Woodard AS, Fornaro M, Tallini G, Languino LR (1999) Prostatic 
carcinoma cell migration via alpha(v)beta3 integrin is modulated by a focal 
adhesion kinase pathway. Cancer Res 59: 1655-1664. 
107. Ishola TA, Kang J, Qiao J, Evers BM, Chung DH (2007) Phosphatidylinositol 3-
kinase regulation of gastrin-releasing peptide-induced cell cycle progression in 
neuroblastoma cells. Biochim Biophys Acta 1770: 927-932. 
108. Kang J, Ishola TA, Baregamian N, Mourot JM, Rychahou PG, et al. (2007) 
Bombesin induces angiogenesis and neuroblastoma growth. Cancer Lett 253: 
273-281. 
109. Brodeur GM (2003) Neuroblastoma: biological insights into a clinical enigma. Nat 
Rev Cancer 3: 203-216. 
110. Qiao J, Kang J, Ishola TA, Rychahou PG, Evers BM, et al. (2008) Gastrin-releasing 
peptide receptor silencing suppresses the tumorigenesis and metastatic potential 
of neuroblastoma. Proc Natl Acad Sci U S A 105: 12891-12896. 
111. Wang D, Grammer JR, Cobbs CS, Stewart JE, Jr., Liu Z, et al. (2000) p125 focal 
adhesion kinase promotes malignant astrocytoma cell proliferation in vivo. J Cell 
Sci 113 Pt 23: 4221-4230. 
 82 
112. Matkowskyj KA, Keller K, Glover S, Kornberg L, Tran-Son-Tay R, et al. (2003) 
Expression of GRP and its receptor in well-differentiated colon cancer cells 
correlates with the presence of focal adhesion kinase phosphorylated at 
tyrosines 397 and 407. J Histochem Cytochem 51: 1041-1048. 
113. Lacoste J, Aprikian AG, Chevalier S (2005) Focal adhesion kinase is required for 
bombesin-induced prostate cancer cell motility. Mol Cell Endocrinol 235: 51-61. 
114. Taglia L, Matusiak D, Matkowskyj KA, Benya RV (2007) Gastrin-releasing peptide 
mediates its morphogenic properties in human colon cancer by upregulating 
intracellular adhesion protein-1 (ICAM-1) via focal adhesion kinase. American 
journal of physiology Gastrointestinal and liver physiology 292: G182-190. 
115. Davidoff AM (2010) Targeting the MYCN effector, FAK, in neuroblastoma. Cell 
Cycle 9: 1026. 
116. Madonna MB (2010) Unraveling the relationship between n-myc and Focal 
Adhesion Kinase (FAK) in neuroblastoma? Cell Cycle 9: 1679-1680. 
117. Gustafson WC, Weiss WA (2010) Myc proteins as therapeutic targets. Oncogene 
29: 1249-1259. 
118. Opel D, Poremba C, Simon T, Debatin KM, Fulda S (2007) Activation of Akt 
predicts poor outcome in neuroblastoma. Cancer Res 67: 735-745. 
119. Chanthery YH, Gustafson WC, Itsara M, Persson A, Hackett CS, et al. (2012) 
Paracrine signaling through MYCN enhances tumor-vascular interactions in 
neuroblastoma. Sci Transl Med 4: 115ra113. 
120. Ponten J (1971) Spontaneous and virus induced transformation in cell culture. Virol 
Monogr 8: 1-253. 
121. Schaller MD, Hildebrand JD, Shannon JD, Fox JW, Vines RR, et al. (1994) 
Autophosphorylation of the focal adhesion kinase, pp125FAK, directs SH2-
dependent binding of pp60src. Mol Cell Biol 14: 1680-1688. 
122. Lightfoot HM, Jr., Lark A, Livasy CA, Moore DT, Cowan D, et al. (2004) 
Upregulation of focal adhesion kinase (FAK) expression in ductal carcinoma in 
situ (DCIS) is an early event in breast tumorigenesis. Breast Cancer Res Treat 
88: 109-116. 
123. Lark AL, Livasy CA, Calvo B, Caskey L, Moore DT, et al. (2003) Overexpression of 
focal adhesion kinase in primary colorectal carcinomas and colorectal liver 
metastases: immunohistochemistry and real-time PCR analyses. Clin Cancer 
Res 9: 215-222. 
 83 
124. Livasy CA, Moore D, Cance WG, Lininger RA (2004) Focal adhesion kinase 
overexpression in endometrial neoplasia. Appl Immunohistochem Mol Morphol 
12: 342-345. 
125. Madan R, Smolkin MB, Cocker R, Fayyad R, Oktay MH (2006) Focal adhesion 
proteins as markers of malignant transformation and prognostic indicators in 
breast carcinoma. Hum Pathol 37: 9-15. 
126. Cheng GZ, Chan J, Wang Q, Zhang W, Sun CD, et al. (2007) Twist transcriptionally 
up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, 
and resistance to paclitaxel. Cancer Res 67: 1979-1987. 
127. Gonzalez E, McGraw TE (2009) The Akt kinases: isoform specificity in metabolism 
and cancer. Cell Cycle 8: 2502-2508. 
128. Rychahou PG, Kang J, Gulhati P, Doan HQ, Chen LA, et al. (2008) Akt2 
overexpression plays a critical role in the establishment of colorectal cancer 
metastasis. Proc Natl Acad Sci U S A 105: 20315-20320. 
129. Foley NH, Bray IM, Tivnan A, Bryan K, Murphy DM, et al. (2010) MicroRNA-184 
inhibits neuroblastoma cell survival through targeting the serine/threonine kinase 
AKT2. Mol Cancer 9: 83. 
130. Tilghman RW, Slack-Davis JK, Sergina N, Martin KH, Iwanicki M, et al. (2005) 
Focal adhesion kinase is required for the spatial organization of the leading edge 
in migrating cells. J Cell Sci 118: 2613-2623. 
131. Lee S, Qiao J, Paul P, O'Connor KL, Evers MB, et al. (2012) FAK is a critical 
regulator of neuroblastoma liver metastasis. Oncotarget 3: 1576-1587. 
132. Qiao J, Paul P, Lee S, Qiao L, Josifi E, et al. (2012) PI3K/AKT and ERK regulate 
retinoic acid-induced neuroblastoma cellular differentiation. Biochem Biophys 
Res Commun 424: 421-426. 
133. London WB, Castel V, Monclair T, Ambros PF, Pearson AD, et al. (2011) Clinical 
and biologic features predictive of survival after relapse of neuroblastoma: a 
report from the International Neuroblastoma Risk Group project. J Clin Oncol 29: 
3286-3292. 
134. Maris GBJ (2006) Neuroblastoma. In: Poplack PPD, editor. Principles and Practice 
of Pediatric Oncology. 530 Walnut Street, Philadelphia, PA 19106 USA: 
Lippincott Williams & Wilkins. pp. 933-970. 
135. Kim C, Ye F, Ginsberg MH (2011) Regulation of integrin activation. Annu Rev Cell 
Dev Biol 27: 321-345. 
 84 
136. Felding-Habermann B (2003) Integrin adhesion receptors in tumor metastasis. Clin 
Exp Metastasis 20: 203-213. 
137. Chirco R, Liu XW, Jung KK, Kim HR (2006) Novel functions of TIMPs in cell 
signaling. Cancer Metastasis Rev 25: 99-113. 
138. Festuccia C, Angelucci A, Gravina G, Eleuterio E, Vicentini C, et al. (2002) 
Bombesin-dependent pro-MMP-9 activation in prostatic cancer cells requires 
beta1 integrin engagement. Exp Cell Res 280: 1-11. 
139. Chao C, Ives K, Hellmich HL, Townsend CM, Jr., Hellmich MR (2009) Gastrin-
releasing peptide receptor in breast cancer mediates cellular migration and 
interleukin-8 expression. J Surg Res 156: 26-31. 
140. Saurin JC, Fallavier M, Sordat B, Gevrey JC, Chayvialle JA, et al. (2002) Bombesin 
stimulates invasion and migration of Isreco1 colon carcinoma cells in a Rho-
dependent manner. Cancer Res 62: 4829-4835. 
141. Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in 
cancer progression. Nat Rev Cancer 2: 161-174. 
142. Deryugina EI, Quigley JP (2006) Matrix metalloproteinases and tumor metastasis. 
Cancer Metastasis Rev 25: 9-34. 
143. Kato H, Liao Z, Mitsios JV, Wang HY, Deryugina EI, et al. (2012) The Primacy of 
beta1 Integrin Activation in the Metastatic Cascade. PLoS One 7: e46576. 
144. Huck L, Pontier SM, Zuo DM, Muller WJ (2010) beta1-integrin is dispensable for the 
induction of ErbB2 mammary tumors but plays a critical role in the metastatic 
phase of tumor progression. Proc Natl Acad Sci U S A 107: 15559-15564. 
145. Shibue T, Weinberg RA (2009) Integrin beta1-focal adhesion kinase signaling 
directs the proliferation of metastatic cancer cells disseminated in the lungs. Proc 
Natl Acad Sci U S A 106: 10290-10295. 
146. Meyer A, van Golen CM, Kim B, van Golen KL, Feldman EL (2004) Integrin 
expression regulates neuroblastoma attachment and migration. Neoplasia 6: 
332-342. 
147. Wang D, Muller S, Amin AR, Huang D, Su L, et al. (2012) The Pivotal Role of 
Integrin beta1 in Metastasis of Head and Neck Squamous Cell Carcinoma. Clin 
Cancer Res 18: 4589-4599. 
148. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 
144: 646-674. 
 85 
149. Talmadge JE, Fidler IJ (2010) AACR centennial series: the biology of cancer 
metastasis: historical perspective. Cancer Res 70: 5649-5669. 
150. Maris JM (2010) Recent advances in neuroblastoma. N Engl J Med 362: 2202-2211. 
151. Luscher B, Larsson LG (1999) The basic region/helix-loop-helix/leucine zipper 
domain of Myc proto-oncoproteins: function and regulation. Oncogene 18: 2955-
2966. 
152. van Noesel MM, Versteeg R (2004) Pediatric neuroblastomas: genetic and 
epigenetic 'danse macabre'. Gene 325: 1-15. 
153. Gupta A, Williams BR, Hanash SM, Rawwas J (2006) Cellular retinoic acid-binding 
protein II is a direct transcriptional target of MycN in neuroblastoma. Cancer 
research 66: 8100-8108. 
154. Kang JH, Rychahou PG, Ishola TA, Qiao J, Evers BM, et al. (2006) MYCN silencing 
induces differentiation and apoptosis in human neuroblastoma cells. Biochem 
Biophys Res Commun 351: 192-197. 
155. Nara K, Kusafuka T, Yoneda A, Oue T, Sangkhathat S, et al. (2007) Silencing of 
MYCN by RNA interference induces growth inhibition, apoptotic activity and cell 
differentiation in a neuroblastoma cell line with MYCN amplification. International 
journal of oncology 30: 1189-1196. 
156. Long W, Yi P, Amazit L, LaMarca HL, Ashcroft F, et al. (2010) SRC-3Delta4 
mediates the interaction of EGFR with FAK to promote cell migration. Molecular 
cell 37: 321-332. 
 
 
